<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-07T16:17:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:amrn="http://www.amarincorp.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="amrn-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1310-Q0010_STD_0_20120131_0_714378x714242" unitRef="pure" decimals="3" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1002_1">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20120131_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1002_0">150000000</us-gaap:DebtInstrumentFaceAmount>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x820302" unitRef="shares" decimals="INF" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1002_500006">468546</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x826933" unitRef="shares" decimals="INF" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_2002_500008">172195467</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20120726_0_735055x740537" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_1004_2">11600000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE46938---1310-Q0010_STD_0_20130712_0_711196x826933" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_2001_1">5.60</us-gaap:SharesIssuedPricePerShare>
  <amrn:OptionsGrantedDuringPeriod contextRef="eol_PE46938---1310-Q0010_STD_0_20130712_0_711196x826933" unitRef="shares" decimals="INF" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_2001_3">3255000</amrn:OptionsGrantedDuringPeriod>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788" unitRef="shares" decimals="1" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_3002_13">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_3002_14">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_3002_12">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788" unitRef="shares" decimals="1" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_4002_7">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_4002_8">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_4002_6">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_711171x716792_714777x781108" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1002_11">0.90</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_711672x709584_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_7F878E9E-D8EE-41BB-9795-4232131D4A48_2003_1">900000</amrn:ClassOfWarrantOrRightIssued>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20091016_0_714777x781108_716763x740788" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_6002_15">35200000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3006_900026">38000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_3004_5">90963000</us-gaap:DerivativeLiabilities>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_3002_36">215110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3004_700026">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3003_600026">613087000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3001_400026">149921422</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3001_500026">124244000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_3005_800026">-737076000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20120930_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_3001_5">90963000</us-gaap:DerivativeLiabilities>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_32">172664013</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_DDE7128E-D36A-49A3-8555-561178852E60_1_1">1.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:SharePrice contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_2_1">6.32</us-gaap:SharePrice>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_36">20079</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_GBP_per_shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_3001_31">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_DDE7128E-D36A-49A3-8555-561178852E60_1_0">9816826</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_33">172643934</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_17">10901000</us-gaap:InterestPayableCurrent>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3005_4">2077000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_28" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_3002_1">7200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_20">31299000</us-gaap:LiabilitiesCurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_23">145316000</us-gaap:SeniorLongTermNotes>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_24">87319000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_19">12548000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_16">6233000</us-gaap:AccountsPayableCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_26">811000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_38">-17697000</us-gaap:StockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_34">739524000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3004_5">47193000</us-gaap:DerivativeLiabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_37">-898459000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_18">1617000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:Liabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_27">311543000</us-gaap:Liabilities>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_1_1">754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_30">141455000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_39">293846000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:InventoryValuationReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6984A716-29BF-44EE-86C4-DC0DAC87190C_1_0">1800000</us-gaap:InventoryValuationReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_11">5335000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_3">1400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_4">3721000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_5">27083000</us-gaap:InventoryNet>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_1_2">9283000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_6">936000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_1_0">4993000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_35">217000</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_9">646000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_10">14433000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_13">293846000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_2">225885000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_12">10870000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_7">3537000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_1_1">12166000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_1_0">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_93C82523-9507-4569-B77F-B34C2F307077_1001_1">641000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1_8">262562000</us-gaap:AssetsCurrent>
  <amrn:CashDiscountPercent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="pure" decimals="2" id="id_2597911_1349199C-F8FD-4AA1-B735-F2AFAE180B22_1001_0">0.02</amrn:CashDiscountPercent>
  <amrn:ExcessFairValueOverPrincipalValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_3_4">42400000</amrn:ExcessFairValueOverPrincipalValue>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_707278x822778_755443x829211" unitRef="iso4217_USD" decimals="-5" id="id_2597911_CDDC2253-BD43-40B8-A3B8-7B4E68FEB086_1001_0">800000</amrn:FutureMinimumGuaranteePayments>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_711502x716112_735055x740537" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_2002_6">10000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_711502x716112_735055x740537" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_2001_6">16100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x779644" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_3002_5">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x779644" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_3001_5">8100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x829979" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_4002_4">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x829979" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_4001_4">8100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:SharePrice contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x784846" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_1002_0">6.95</us-gaap:SharePrice>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x830088_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_2001_4">3900000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x779644" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_5002_1">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x779644" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_5001_1">12100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x829979" unitRef="iso4217_GBP" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_6002_0">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x829979" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_6001_0">12100000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7004_700013">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7003_600013">739524000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7001_400013">172664013</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7001_500013">141455000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_7005_800013">-898459000</us-gaap:StockholdersEquity>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x709050" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3001_4">888000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x713749" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3003_4">72000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x824442" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3004_4">183000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x825682" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_3002_4">934000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715225" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1001_25">7200000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2001_22">39598000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_711502x716112_714777x781108_716763x740788" unitRef="shares" decimals="-5" id="id_2597911_7B4516AF-319C-4ECD-BD82-57CF9AFE62A0_1001_0">36100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_711672x709584_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_7F878E9E-D8EE-41BB-9795-4232131D4A48_2001_2">600000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_3">39600000</us-gaap:DerivativeLiabilities>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_5">400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_4">7200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_1_1">113500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_2_1">113500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_4_3">39600000</us-gaap:DerivativeLiabilities>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_4_5">400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7E3A309C-E704-4A5D-B78E-6E0066F0D1C2_4_4">7200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1004_2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1004_1">627050</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1004_3">10/15/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1002_2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1002_1">1684888</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1002_3">7/30/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1001_2">17.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1001_1">17500</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1001_3">1/17/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1003_2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234" unitRef="shares" decimals="INF" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1003_1">7487388</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:ClassOfWarrantOrRightExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234" id="id_2597911_A5FFB13A-58DE-4C66-BB7C-43E94C87A519_1003_3">10/15/14</amrn:ClassOfWarrantOrRightExpirationDate>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="pure" decimals="3" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_3001_3">0.145</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_3001_7">1100000</us-gaap:InterestPayableCurrent>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_3001_2">145300000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_3001_1">126200000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_3001_1">800000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_714777x781108_716763x740788" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_6003_16">7500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x710071" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3003_5">395000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3002_5">7200000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3004_2">7200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeAssetNotionalAmount contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_2001_0">4500000</us-gaap:DerivativeAssetNotionalAmount>
  <us-gaap:ForeignCurrencyDerivativesAtFairValueNet contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_2001_2">400000</us-gaap:ForeignCurrencyDerivativesAtFairValueNet>
  <amrn:NumberOfForeignCurrencyForwardContractsOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981" unitRef="Contract" decimals="INF" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_2001_1">1</amrn:NumberOfForeignCurrencyForwardContractsOutstanding>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_3001_5">39598000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20130930_0_716763x715581" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_2001_0">39600000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1006_900014">-5962000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_1004_1">123125000</us-gaap:DerivativeLiabilities>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_4001_35">116602000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1004_700014">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1003_600014">449393000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1001_400014">135832542</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1001_500014">113321000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_1005_800014">-568459000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20111231_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_1001_1">123125000</us-gaap:DerivativeLiabilities>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_32">150360933</us-gaap:CommonStockSharesIssued>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_36">20079</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_GBP_per_shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_3002_31">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_33">150340854</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_17">2520000</us-gaap:InterestPayableCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_28" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_20">25202000</us-gaap:LiabilitiesCurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_23">134250000</us-gaap:SeniorLongTermNotes>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_24">85153000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_19">5224000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_16">17458000</us-gaap:AccountsPayableCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_26">816000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_38">-3997000</us-gaap:StockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_34">619266000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_1004_1">69431000</us-gaap:DerivativeLiabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_37">-747643000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_1_0">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:Liabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_27">314852000</us-gaap:Liabilities>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_2_1">269000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_30">124597000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_39">310855000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_11">4951000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_5">21262000</us-gaap:InventoryNet>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_2_2">326000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_6">937000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_2_0">5465000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_35">217000</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_9">811000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_10">8044000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_13">310855000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_2">260242000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_12">11355000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_7">3253000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_496CD27E-C265-4A5B-9299-92FB1C0BEBDF_2_1">15471000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7B444E14-2115-4D5C-B17C-9B3DA6FC21FF_2_0">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2_8">285694000</us-gaap:AssetsCurrent>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778" unitRef="iso4217_USD" decimals="-6" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1001_1">150000000</us-gaap:OtherCommitment>
  <amrn:ChangeInControlObligations contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778" unitRef="iso4217_USD" decimals="-6" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1001_8">140000000</amrn:ChangeInControlObligations>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x735492" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_3001_3">8000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x770088" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_4001_4">10000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x796385" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_5001_6">13000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x824056" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_6001_5">15000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x829211" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_7001_2">2500000</amrn:FutureMinimumGuaranteePayments>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x708572" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5004_700001">-217000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5003_600001">619266000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5001_400001">150360933</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5001_500001">124597000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_5005_800001">-747643000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715225" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_1002_25">14577000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FFF7B51B-D391-487E-A23D-ED6B32F8D1A6_2002_22">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_1_3">54900000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_1_4">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_1_1">64100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_2_1">64100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_4_3">54900000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-5" id="id_2597911_38A77765-DC80-471A-84B5-C1BA6A3A19FA_4_4">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <amrn:AdditionalPercentageInterestRatePenalty contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_714378x714242" unitRef="pure" decimals="4" id="id_2597911_3DD88501-E130-4B19-9C2D-962B239A5397_1001_0">0.0050</amrn:AdditionalPercentageInterestRatePenalty>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-6" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3002_1">150000000</us-gaap:OtherCommitment>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_1002_1">14577000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3002_10">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <amrn:ChangeInControlObligations contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232" unitRef="iso4217_USD" decimals="-6" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3002_0">140000000</amrn:ChangeInControlObligations>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_1001_1">54854000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1310-Q0010_STD_0_20121231_0_716763x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1001_0">54854000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_4CBDAAEF-95FB-4C02-AFC3-583D5EB15E1E_2_1">121200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933" unitRef="shares" decimals="INF" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_1001_0">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_1001_2">121200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <amrn:OptionsExercisablePeriod contextRef="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933" id="id_2597911_1D61FE80-A594-44A7-A935-1CB6D6D7D63F_1001_4">P30D</amrn:OptionsExercisablePeriod>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="eol_PE46938---1310-Q0010_STD_22_20131022_0_710720x714667" unitRef="pure" decimals="2" id="id_2597911_D268E364-FF07-42AE-AD68-34F990115211_1001_0">0.50</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
  <us-gaap:RestructuringAndRelatedCostExpectedCost contextRef="eol_PE46938---1310-Q0010_STD_22_20131022_0_710720x714667" unitRef="iso4217_USD" decimals="-6" id="id_2597911_D268E364-FF07-42AE-AD68-34F990115211_1001_1">3000000</us-gaap:RestructuringAndRelatedCostExpectedCost>
  <dei:TradingSymbol contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400000">AMRN</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400001">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400004">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400002">0000897448</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_74C72283-5A7D-4033-87E4-AE6EFDCA23FC_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A53FE596-E0EC-4849-B468-3BE46E1D088A_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A64BDB45-B941-4889-B4EE-414D5DB3DB47_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
 of a milestone payment paid to the former shareholders of Laxdale
 Limited related to the 2004 acquisition of our rights to Vascepa,
 which is the result of Vascepa receiving marketing approval for the
 first indication and is amortized over its estimated useful life on
 a straight-line basis. The Company concluded that use of the
 straight-line method was appropriate as the majority of cash flows
 are expected to be generated ratably over the estimated useful life
 and no degradation of the cash flows over time is currently
 anticipated. See Note 7&amp;#x2014;Commitments and Contingencies for
 further information regarding other obligations related to the
 acquisition of Laxdale Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:DebtPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_578464EA-926A-4F73-A31D-62058E2EADB4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the statement
 of operations as interest expense at each period end while such
 instruments are outstanding. If the Company issues shares to
 discharge the liability, the debt obligation is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 exchangeable notes contain a conversion option which is classified
 as equity. The fair value of the liability component of the debt
 instrument was deducted from the initial proceeds to determine the
 proceeds to be allocated to the conversion option. The embedded
 conversion option is indexed to the Company&amp;#x2019;s stock and
 treated as equity on the balance sheet. The conversion option is
 evaluated on a quarterly basis to determine if it still meets the
 criteria to be equity classified. The excess principal amount of
 the debt over the carrying value of the liability is amortized to
 interest expense over the term of the debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 debt financing agreement contains a redemption
 feature triggered upon a change of control, which has been
 classified as an embedded derivative. The fair value of the
 derivative was recorded as a reduction to the fair value of the
 note payable. The fair value of this warrant derivative liability
 is remeasured at each reporting period, with changes in fair value
 recognized in the statement of operations. The discount recorded to
 the note payable is being amortized to interest expense over the
 term of the note payable.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_65EFD2A1-8064-4E64-877B-7F25E20FCDA9_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(6)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Long term
 debt&amp;#x2014;December 2012 Financing&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On December&amp;#xA0;6, 2012,
 the Company entered into an agreement with BioPharma. Under this
 agreement, the Company granted to BioPharma a security interest in
 future receivables associated with the Vascepa patent rights in
 exchange for $100.0 million received at the closing of the
 agreement, which closing occurred in December 2012. The Company has
 agreed to repay BioPharma up to $150&amp;#xA0;million of future revenue
 and receivables. The first scheduled repayment under the agreement
 is a repayment of $2.5&amp;#xA0;million of interest due to be paid to
 BioPharma in November 2013 for the fiscal quarter ended
 September&amp;#xA0;30, 2013, subject to the limitation described below.
 Additional quarterly repayments are scheduled to be paid thereafter
 in accordance with the following schedule: $2.5 million of interest
 in the first quarter of 2014; $8.0 million per quarter in each of
 the next four quarters, $10.0 million per quarter in each of the
 next four quarters, $15.0 million per quarter in each of the next
 four quarters and a final payment of $13.0 million scheduled for
 payment in May 2017. The quarterly repayments through the third
 quarter of September 2014 represent interest only. Quarterly
 payments do not begin to reduce the principal balance until the
 fourth quarter of 2014. These quarterly payments are subject to a
 quarterly threshold amount whereby, if a calculated threshold,
 based on quarterly Vascepa revenues, is not achieved, the quarterly
 payment payable in that quarter can at the Company&amp;#x2019;s election
 be reduced, with the reduction carried forward without interest for
 payment in a future period. The payment of any carried forward
 amount is subject to similarly calculated threshold repayment
 amounts based on Vascepa revenue levels. Except upon a change of
 control in Amarin, the agreement does not expire until $150 million
 has been repaid. Under the agreement, upon a change of control, the
 Company would be required to pay $140 million, less any previously
 repaid amount, if the change of control occurs on or before
 December&amp;#xA0;31, 2013, or required to repay $150 million, less any
 previously repaid amount, if the change of control event occurs
 after December&amp;#xA0;31, 2013. The Company can prepay after
 October&amp;#xA0;1, 2013, an amount equal to $150 million less any
 previously repaid amount.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company determined the
 redemption feature upon a change of control to be an embedded
 derivative requiring bifurcation. The fair value of the embedded
 derivative was calculated by determining the fair value of the debt
 with the change in control provision included and also without the
 change in control provision. The difference between the two fair
 values of the debt was determined to be the fair value of the
 embedded derivative, and upon closing, the Company recorded a
 derivative liability of $14.6 million as a reduction to the note
 payable. The fair value of this derivative liability is remeasured
 at each reporting period, with changes in fair value recognized in
 the statement of operations. The fair value of the derivative
 liability at September&amp;#xA0;30, 2013 was $7.2 million and the
 Company recognized a gain on change in fair value of derivative
 liability of $1.4 million and $7.4 million for the three and nine
 month periods ended September&amp;#xA0;30, 2013, respectively. For the
 nine months ended September&amp;#xA0;30, 2013, the Company recorded
 $9.7&amp;#xA0;million and $2.2 million of cash and non-cash interest
 expense, respectively related to the BioPharma debt. For the three
 months ended September&amp;#xA0;30, 2013, the Company recorded
 $2.7&amp;#xA0;million and $0.6 million of cash and non-cash interest
 expense, respectively related to the BioPharma debt. The Company
 will periodically evaluate the remaining term of the agreement and
 the effective interest will be recalculated each period based on
 the Company&amp;#x2019;s most current estimate of repayment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company currently
 estimates that its Vascepa revenue levels will not be high enough
 in each quarter to support repayment to BioPharma in accordance
 with threshold amounts in the repayment schedule. For the three
 months ended September&amp;#xA0;30, 2013, revenues were below the
 contractual threshold amount such that a cash payment of $0.8
 million is due in November 2013 reflecting the calculated optional
 reduction amount as opposed to the contractual threshold payment of
 $2.5 million. In accordance with the agreement with BioPharma,
 quarterly differences between the calculated optional reduction
 amounts and the repayment schedule amounts are rescheduled for
 payment beginning in the second quarter of 2017. Any such deferred
 repayments will remain subject to continued application of the
 quarterly ceiling in amounts due established by the calculated
 threshold based on quarterly Vascepa revenues. Additionally, the
 revised assumptions yielded a decrease in the calculated effective
 interest rate resulting in a decrease in interest expense during
 the three months ended September&amp;#xA0;30, 2013 as compared to the
 three months ended June&amp;#xA0;30, 2013 and March&amp;#xA0;31,
 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2012, the Company
 issued $150.0 million in principal amount of 3.5% exchangeable
 senior notes due 2032, or the Senior Notes. The Senior Notes were
 issued by Corsicanto Limited, an Irish limited company acquired by
 Amarin in January 2012. Corsicanto Limited is a wholly-owned
 subsidiary of Amarin. The general, unsecured, senior obligations
 are fully and unconditionally guaranteed by Amarin but not by any
 of the Company&amp;#x2019;s subsidiaries. Corsicanto Limited has no
 assets, operations, revenues or cash flows other than those related
 to the issuance, administration and repayment of the Senior
 Notes.&amp;#xA0;There are no significant restrictions on the ability of
 Amarin to obtain funds from Corsicanto Limited in the form of cash
 dividends, loans, or advances.&amp;#xA0;Net proceeds to the Company,
 after payment of underwriting fees and expenses, were approximately
 $144.3 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Senior Notes have a
 stated interest rate of 3.5%&amp;#xA0;per year, payable semiannually in
 arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year beginning
 on July&amp;#xA0;15, 2012, and ending upon the Senior Notes&amp;#x2019;
 maturity on January&amp;#xA0;15, 2032. The Senior Notes are subject to
 repurchase by the Company at the option of the holders on each of
 January&amp;#xA0;19, 2017,&amp;#xA0;January&amp;#xA0;19, 2022, and
 January&amp;#xA0;19, 2027, at a price equal to 100% of the principal
 amount of the Senior Notes to be repurchased, plus accrued and
 unpaid interest to, but excluding, the repurchase date. The Senior
 Notes are exchangeable under certain circumstances into cash, ADSs,
 or a combination of cash and ADSs, at the Company&amp;#x2019;s election,
 with an initial exchange rate of 113.4752 ADSs per $1,000 principal
 amount of Senior Notes. It is the Company&amp;#x2019;s current intention
 to settle these obligations in cash. If the Company elected
 physical settlement, the Senior Notes would initially be
 exchangeable into 17,021,280 ADSs. Based on the closing price of
 the Company&amp;#x2019;s stock at September&amp;#xA0;30, 2013, the principal
 amount of the Senior Notes would exceed the value of the shares if
 converted on that date by $42.4 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Additional covenants
 include: (i)&amp;#xA0;limitations on future indebtedness under certain
 circumstances, (ii)&amp;#xA0;the timely filing of documents and reports
 pursuant to Section&amp;#xA0;13 or 15(d) of the Exchange Act with both
 the SEC and the Trustee, and (iii)&amp;#xA0;maintaining the tradability
 of the Senior Notes. The Company is required to use commercially
 reasonable efforts to procure and maintain the listing of the
 Senior Notes on the Global Exchange Market operated under the
 supervision of the Irish Stock Exchange (or other recognized stock
 exchange as defined in the Note Indenture) prior to July&amp;#xA0;15,
 2012. If the Senior Notes are not freely tradable, as a result of
 restrictions pursuant to U.S. securities law or the terms of the
 Indenture or the Senior Notes, the Company shall pay additional
 interest on the Senior Notes at the rate of 0.50%&amp;#xA0;per annum of
 the principal amount of Senior Notes outstanding for each day
 during such period for which the Company&amp;#x2019;s failure to file
 has occurred and is continuing or for which the Senior Notes are
 not freely tradable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company may not redeem
 the Senior Notes prior to January&amp;#xA0;19, 2017, other than in
 connection with certain changes in the tax law of a relevant taxing
 jurisdiction that results in additional amounts becoming due with
 respect to payments and/or deliveries on the Senior Notes. On or
 after January&amp;#xA0;19, 2017 and prior to the maturity date, the
 Company may redeem for cash all or part of the Senior Notes at a
 redemption price equal to 100% of the principal amount of the
 Senior Notes to be redeemed, plus accrued and unpaid interest to,
 but excluding, the redemption date. There is no prepayment penalty
 or sinking fund provided for the Senior Notes. If the Company
 undergoes a fundamental change, holders may require the Company to
 repurchase for cash all or part of their Senior Notes at a
 repurchase price equal to 100% of the principal amount of the
 Senior Notes to be repurchased, plus accrued and unpaid interest
 to, but excluding, the fundamental change repurchase date. The
 Senior Notes are the Company&amp;#x2019;s senior unsecured obligations
 and rank senior in right of payment to the Company&amp;#x2019;s future
 indebtedness that is expressly subordinated in right of payment to
 the Senior Notes and equal in right of payment to the
 Company&amp;#x2019;s future unsecured indebtedness that is not so
 subordinated. The Senior Notes are effectively junior in right of
 payment to future secured indebtedness to the extent of the value
 of the assets securing such indebtedness.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Senior Notes are
 exchangeable under certain circumstances. The Company calculated
 the fair value of the liability component of the Senior Notes to be
 $126.2 million, and the excess of the principal amount of the debt
 over the liability component of $23.8 million was allocated to the
 conversion option resulting in a discount on the debt. The discount
 created from allocating proceeds to the conversion option is being
 amortized to interest expense using the effective interest method
 over the Senior Notes&amp;#x2019; estimated remaining life, which was
 calculated to be a period of twenty-four months. The effective
 interest rate of the Senior Notes is 14.5%. As of
 September&amp;#xA0;30, 2013, the unamortized discount created from the
 allocation of the proceeds to the conversion option was $3.9
 million. The conversion option will not be subsequently remeasured
 as long as it continues to meet the criteria for equity
 classification.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company also recorded a
 debt discount to reflect the value of the underwriters&amp;#x2019;
 discounts and offering costs. A portion of the debt discount from
 underwriter&amp;#x2019;s discounts and offering costs was allocated to
 the equity and liability components of the Notes in proportion to
 the proceeds allocated to each component. The portion of the debt
 discount from underwriters&amp;#x2019; discounts and offering costs
 allocated to the liability component is being amortized as interest
 expense over the estimated remaining life of the Senior Notes of
 twenty-four months. As of September&amp;#xA0;30, 2013, the unamortized
 debt discount was $0.8 million and was recorded as a direct
 reduction of the related debt on the balance sheet. The carrying
 value of the Notes, net of the unamortized discount, was $145.3
 million. During the three months ended September&amp;#xA0;30, 2013, the
 Company recognized interest expense of $5.2 million related to the
 Notes, of which $3.2 million represents amortization of the debt
 discount created upon allocation of proceeds to the conversion
 option, $1.3 million represents contractual coupon interest, and
 $0.7 million represents the amortization of the discount from the
 underwriter&amp;#x2019;s discounts and offering costs. During the nine
 months ended September&amp;#xA0;30, 2013, the Company recognized
 interest expense of $15.0 million related to the Notes, of which
 $9.2 million represents amortization of the debt discount created
 upon allocation of proceeds to the conversion option, $3.9 million
 represents contractual coupon interest, and $1.9 million represents
 the amortization of the discount from the underwriter&amp;#x2019;s
 discounts and offering costs. At September&amp;#xA0;30, 2013, the
 Company had accrued interest of $1.1 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January and July 2013,
 the interest payments due of $2.6 million were paid as
 scheduled.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_1DB718A5-8EB7-48E1-BF0A-4FE847B5B501_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors, that in turn resell Vascepa to
 retail pharmacies for subsequent resale to patients and health care
 providers. Patients are required to have a prescription in order to
 purchase Vascepa. In accordance with GAAP, the Company&amp;#x2019;s
 revenue recognition policy requires that: (i)&amp;#xA0;there is
 persuasive evidence that an arrangement exists between the Company
 and the Distributor, (ii)&amp;#xA0;delivery has occurred,
 (iii)&amp;#xA0;collectability is reasonably assured and (iv)&amp;#xA0;the
 price is fixed or determinable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company commenced its
 commercial launch in the United States on January&amp;#xA0;28, 2013.
 Prior to 2013, the Company recognized no revenue from Vascepa
 sales. In accordance with GAAP, until the Company has the ability
 to reliably estimate returns of Vascepa from its Distributors,
 revenue will be recognized based on the resale of Vascepa for the
 purposes of filling patient prescriptions, and not based on sales
 from the Company to such Distributors. Consistent with industry
 practice, once the Company achieves sufficient history such that it
 can reliably estimate returns, the Company will recognize revenue
 based on sales to its Distributors. The Company currently defers
 Vascepa revenue recognition until the earlier of the product being
 resold for purposes of filling patient prescriptions; or the
 expiration of the right of return (twelve months after the
 expiration date of the product). The Company also defers the
 related cost of product sales and records such amounts as finished
 goods inventory held by others until revenue related to such
 product sales is recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contracts
 with its primary Distributors and delivery occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment or when the product is utilized.
 In order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&amp;#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&amp;#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues based on the wholesale acquisition cost that the
 Company charges its Distributors for Vascepa. The Company estimates
 its net product revenues by deducting from its gross product
 revenues (a)&amp;#xA0;trade allowances, such as invoice discounts for
 prompt payment and distributor fees, (b)&amp;#xA0;estimated government
 and private payor rebates, chargebacks and discounts, such as
 Medicaid reimbursements, (c)&amp;#xA0;reserves for expected product
 returns and (d)&amp;#xA0;estimated costs of incentives offered to
 certain indirect customers, including patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
 Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within
 30&amp;#xA0;days. Based on the Company&amp;#x2019;s judgment and experience,
 the Company expects its Distributors to earn these discounts and
 fees, and deducts the full amount of these discounts and fees from
 its gross product revenues and accounts receivable at the time such
 revenues are recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
 Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s contracts with these
 Third-party Payors, (ii)&amp;#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&amp;#xA0;information
 obtained from the Company&amp;#x2019;s Distributors and
 (iv)&amp;#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the 18-month period
 beginning six months prior to the labeled expiration date and
 ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. As of
 September&amp;#xA0;30, 2013, the Company had experienced a deminimus
 quantity of product returns. During the nine months ended
 September&amp;#xA0;30, 2013, the period in which the Company began
 selling Vascepa, the Company was not able to reasonably estimate
 product returns for all product sold to Distributors but the
 Company was able to reasonably estimate product returns for certain
 sales of Vascepa based on product used to fill patient
 prescriptions as determined by inventory estimated to be in the
 distribution channel and third party reports of prescriptions
 filled. In making this assessment, the Company used (i)&amp;#xA0;data
 provided to the Company by its Distributors (including weekly
 reporting of Distributors&amp;#x2019; sales and inventory held by
 Distributors that provided the Company with visibility into the
 distribution channel in order to determine what quantities were
 sold to retail pharmacies and other providers),
 (ii)&amp;#xA0;information provided to the Company from retail
 pharmacies, (iii)&amp;#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&amp;#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&amp;#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s
 Distributors.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
 Incentives:&amp;#xA0;&lt;/i&gt;Other incentives that the Company offers to
 indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&amp;#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&amp;#x2019;s portion of the
 financial responsibility for Vascepa&amp;#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company&amp;#x2019;s co-pay mitigation rebates offered
 to date will expire on December&amp;#xA0;31, 2013. The Company adjusts
 its accruals for co-pay mitigation rebates based on its estimates
 regarding the portion of issued rebates that it estimates will not
 be redeemed. In addition, as is customary prior to the launch of
 new drugs, the Company provided certain of its Distributors with
 financial incentives to begin stocking Vascepa prior to the
 Company&amp;#x2019;s commercial launch of Vascepa in order to ensure
 that Vascepa was readily available to fill patient prescriptions
 upon launch. Such incentives were only offered on purchases of
 initial launch quantities of Vascepa stocked by Distributors in
 January 2013. The amount of these financial incentives were
 recorded by the Company as a reduction to revenues on a pro-rata
 basis for each of the bottles subject to such financial incentives.
 The Company estimates that all of these initial launch quantities
 stocked by its primary Distributors in January 2013 were resold by
 such Distributors prior to September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,418&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,347&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,484&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,835&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;888&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;183&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,077&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product revenue
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred product
 revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,617&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;17,862&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 Company&amp;#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&amp;#xA0;30, 2013 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods sold
 expensed&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,813&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,454&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_4">0.91</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_E7F46C52-BD98-489C-9FC3-86D68D77210A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had 9,816,826
 warrants to purchase common shares outstanding at
 September&amp;#xA0;30, 2013 at a weighted-average exercise price of
 $1.44, as summarized in the following table:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
 &lt;tr&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Issue
 Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4/27/07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17.90&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1/17/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/31/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,684,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/30/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,487,388&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;627,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,816,826&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1.44&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_384953FF-8901-4154-B43B-51A2260DBF0C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventories consist of the
 following at September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,993&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,465&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in process&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,166&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,283&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;326&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,083&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,262&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_18CC318F-1DCB-48F0-95C2-1FBD25DC93D2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of financial instruments is as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
 value of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,577&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,431&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,077&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,377&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;395&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;39,598&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,200&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;395&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;47,193&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_A6512D9D-1A64-4E3D-8571-AA55DDD825D4_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(5)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Warrants and Warrant
 Derivative Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had 9,816,826
 warrants to purchase common shares outstanding at
 September&amp;#xA0;30, 2013 at a weighted-average exercise price of
 $1.44, as summarized in the following table:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
 &lt;tr&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 17pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 14pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 24pt"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="23%"&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td style="WIDTH: 27pt"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Issue
 Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="4" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4/27/07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17.90&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1/17/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/31/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,684,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7/30/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,487,388&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/16/09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;627,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.50&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10/15/14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,816,826&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1.44&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;October
 2009 Warrant derivative liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On October&amp;#xA0;16, 2009,
 the Company completed a $70.0 million private placement with both
 existing and new investors resulting in $62.3 million in net
 proceeds and an additional $3.6 million from bridge notes converted
 in conjunction with the private placement. In consideration for the
 $62.3 million in net cash proceeds Amarin issued 66.4&amp;#xA0;million
 units, each unit consisting of (i)&amp;#xA0;one ADS (representing one
 ordinary share) at a purchase price of $1.00 and (ii)&amp;#xA0;a
 warrant with a five year term to purchase 0.5 of an ADS at an
 exercise price of $1.50 per ADS. In consideration for the
 conversion of $3.6 million of convertible bridge notes, Amarin
 issued 4.0&amp;#xA0;million units, each unit consisting of (i)&amp;#xA0;one
 ADS (representing one ordinary share) at a purchase price of $0.90
 and (ii)&amp;#xA0;a warrant with a five year term to purchase 0.5 of an
 ADS at an exercise price of $1.50 per ADS. The total number of
 warrants issued in conjunction with the financing was
 35.2&amp;#xA0;million of which 7.5&amp;#xA0;million are outstanding at
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 October 2009 financing, the Company issued an additional
 0.9&amp;#xA0;million warrants to three former officers of which
 0.6&amp;#xA0;million are outstanding as of September&amp;#xA0;30, 2013. The
 warrants issued in connection with the October 2009 financing
 contained a pricing variability feature which provided for an
 increase to the exercise price if the exchange rate between the
 U.S. dollar and British pound adjusts such that the warrants could
 be exercised at a price less than the &amp;#xA3;0.5 par value of the
 common stock &amp;#x2013; that is, if the exchange rate exceeded U.S.
 $3.00 per &amp;#xA3;1.0 sterling. Due to the potential variable nature
 of the exercise price, the warrants are not considered to be
 indexed to the Company&amp;#x2019;s common stock. Accordingly, the
 warrants do not qualify for the exception to classify the warrants
 within equity and are classified as a derivative
 liability.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of this
 warrant derivative liability is remeasured at each reporting
 period, with changes in fair value recognized in the statement of
 operations. Upon exercise, the fair value of the warrants exercised
 is remeasured and reclassified from warrant liability to additional
 paid-in capital. Although the warrants contain a pricing
 variability feature, the number of warrants issuable remains fixed.
 Therefore, the maximum number of common shares issuable as a result
 of the October 2009 private placement is 36.1 million. The change
 in fair value of the warrant derivative liability is discussed in
 Note 2.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;July 2009
 and April 2007 Warrants&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company issued certain
 warrants in July 2009 and April 2007. As of September&amp;#xA0;30, 2013
 and December&amp;#xA0;31, 2012 these warrants have been classified as
 equity instruments and have been included in the Company&amp;#x2019;s
 consolidated balance sheet within additional paid-in-capital.
 During the nine months ended September&amp;#xA0;30, 2013, 120,000 of
 the July 2009 warrants were exercised resulting in proceeds to the
 Company of $0.1 million.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="-6" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_3">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:DerivativesEmbeddedDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_6B36ECFA-67A1-4F50-B4F4-060BF42A31C1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long
 Term Debt Redemption Feature&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman, L.P, or BioPharma, contains a redemption
 feature whereby, upon a change of control, the Company would be
 required to pay $140 million, less any previously repaid amount, if
 the change of control occurs on or before December&amp;#xA0;31, 2013,
 or required to repay $150 million, less any previously repaid
 amount, if the change of control event occurs after
 December&amp;#xA0;31, 2013. The Company determined this redemption
 feature to be an embedded derivative, which is carried at fair
 value and is classified as Level 3 in the fair value hierarchy due
 to the use of significant unobservable inputs.&amp;#xA0;The fair value
 of the embedded derivative was calculated using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two fair values of the debt was
 determined to be the fair value of the embedded derivative. At
 December&amp;#xA0;31, 2012, the fair value of the derivative was
 determined to be $14.6 million, and the debt was valued by
 comparing debt issues of similar companies with (i)&amp;#xA0;terms of
 between 4.8 and 8.0 years, (ii)&amp;#xA0;coupon rates of between 3.0%
 and 11.5% and (iii)&amp;#xA0;market yields of between 10.7% and 27.7%.
 At September&amp;#xA0;30, 2013, the fair value of the derivative was
 determined to be $7.2 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&amp;#xA0;remaining terms of
 between 3.5 and 4.4 years, (ii)&amp;#xA0;coupon rates of between 9.9%
 and 12.5% and (iii)&amp;#xA0;market yields of between 10.4% and 25.8%.
 The Company recognized a gain of $1.4 million and $7.4 million on
 the change in fair value of this derivative liability for the three
 and nine months ended September&amp;#xA0;30, 2013,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativesEmbeddedDerivatives>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_E6328F84-C10A-4501-937F-997914A61836_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
 Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carry-forwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&amp;#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_5A5093AC-2FDD-49E6-8396-D439A72F6CC3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
 Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges sales,
 general and administrative costs to operations as incurred.
 Selling, general and administrative costs include costs of
 salaries, programs and infrastructure necessary for the general
 conduct of the Company&amp;#x2019;s business, including the 2013
 commercial launch of Vascepa in the United States for the MARINE
 indication. Included as part of selling, general and administrative
 costs is warrant-related expense from non-cash changes in fair
 value of the derivative liability associated with warrants issued
 in October 2009 to former officers of Amarin which is recorded as
 compensation income (expense).&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_2D60251D-CEE9-4F58-935B-AADDCF29ABDB_1_0">P16Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_43097B0B-FE68-4CA0-95D0-A09E29308B70_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents information about the Company&amp;#x2019;s assets and
 liabilities as of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
 contracts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_3086312D-8916-4FC6-AE46-1D1303AD63B9_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(4)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;After approval of Vascepa
 on July&amp;#xA0;26, 2012 by the FDA, the Company began capitalizing
 its purchases of saleable inventory of Vascepa from suppliers that
 have been qualified by the FDA. Inventories consist of the
 following at September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,993&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,465&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in process&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,166&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,471&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,283&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;326&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,083&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,262&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventory is valued at
 lower of cost or market value. During the three months ended
 September&amp;#xA0;30, 2013, the Company recorded an inventory reserve
 of $1.8 million related to certain inventories that are not
 recoverable in their current form. The materials are currently
 under investigation by the supplier and the Company. The reserve
 was recorded within research and development expense in the
 statement of operations as this supplier has yet to produce
 material qualified for commercial sale.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_EACE6450-13EA-4D30-81D1-0E0C86A1F0BC_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(8)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Equity&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Common
 stock&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On July&amp;#xA0;12, 2013, the
 Company completed a public offering of 21,700,000 ADSs. The
 underwriters purchased the ADSs from Amarin at a price of $5.60 per
 ADS, resulting in net proceeds to Amarin of approximately $121.2
 million, after deducting estimated offering expenses payable by the
 Company. Amarin also granted the underwriters a 30-day option to
 purchase an additional 3,255,000 ADSs, which was not exercised. The
 stated use of proceeds in connection with this offering were as
 follows: primarily to continue the commercial launch of Vascepa
 capsules in the MARINE indication, prepare for and commercially
 launch Vascepa in the ANCHOR indication, if approved, advance the
 Company&amp;#x2019;s REDUCE-IT cardiovascular outcomes trial, and for
 general corporate and working capital purposes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, the Company issued 386,000 and
 3,107,913 shares, respectively, as a result of the exercise of
 stock options. Gross and net proceeds resulting from the exercise
 of stock options amounted to $0.6 million for the nine months ended
 September&amp;#xA0;30, 2013. For the nine months ended
 September&amp;#xA0;30, 2012, gross proceeds amounted to $7.9 million
 and net proceeds amounted to $7.8 million resulting from the
 exercise of stock options. In addition, during the nine months
 ended September&amp;#xA0;30, 2013 and 2012, the Company issued 120,000
 and 10,881,276 shares, respectively, as a result of the exercise of
 warrants. Gross and net proceeds resulting from the exercise of
 warrants amounted to $0.1 million for the nine months ended
 September&amp;#xA0;30, 2013. For the nine months ended
 September&amp;#xA0;30, 2012, gross proceeds amounted to $16.6 million
 and net proceeds amounted to $16.5 million resulting from the
 exercise of warrants.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In August and September of
 2013, the Company granted a total of 44,000 restricted stock units
 (&amp;#x201C;RSUs&amp;#x201D;) to several employees under the Amarin
 Corporation plc 2011 Stock Incentive Plan (&amp;#x201C;2011
 Plan&amp;#x201D;). As of September&amp;#xA0;30, 2013, no RSU&amp;#x2019;s were
 forfeited and no shares were issued as a result of vesting. These
 RSUs vest upon the achievement of certain operational milestones
 and expire on December&amp;#xA0;31, 2013 if none of the milestones are
 achieved by such date. The RSUs will become fully vested upon a
 change of control of the Company. Upon vesting of each RSU, the
 participant shall be entitled to a payment equal to the fair market
 value of one share of Amarin common stock. The payment shall be
 paid to the participant in cash, or at the sole discretion of the
 Compensation Committee in shares or a combination of cash or
 shares. The fair value of the RSUs was determined on the date of
 grant, and compensation expense related to the RSUs is recognized
 once the related milestone is deemed probable. The Company recorded
 no expense during the nine months ended September&amp;#xA0;30, 2013
 related to the vesting of these RSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In July of 2013, the Company
 granted a total of 54,000 deferred stock units (&amp;#x201C;DSUs&amp;#x201D;)
 to members of the Company&amp;#x2019;s Board of Directors under the
 Amarin Corporation plc 2011 Stock Incentive Plan (&amp;#x201C;2011
 Plan&amp;#x201D;). As of September&amp;#xA0;30, 2013, no DSU&amp;#x2019;s were
 forfeited and no shares were issued as a result of vesting. The
 DSU&amp;#x2019;s vest over a three year period. The DSUs will become
 fully vested upon a change of control of the Company. Upon
 termination of service to the Company, each Director shall be
 entitled to a payment equal to the fair market value of one share
 of Amarin common stock, which is required to be made in shares. The
 Company recorded expense during the nine months ended
 September&amp;#xA0;30, 2013 of $47,000 related to the vesting of these
 DSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2013, the Company
 granted 454,875 RSUs to several employees under the 2011 Plan. As
 of September&amp;#xA0;30, 2013, 32,500 RSUs were forfeited and no
 shares were issued as a result of vesting. These RSUs vest upon the
 achievement of certain operational milestones and expire on
 August&amp;#xA0;3, 2015 if none of the milestones are achieved by such
 date. The RSUs will become fully vested upon a change of control of
 the Company. Upon vesting of each RSU, the participant shall be
 entitled to a payment equal to the fair market value of one share
 of Amarin common stock. The payment shall be paid to the
 participant in cash, or at the sole discretion of the Compensation
 Committee in shares or a combination of cash or shares. The fair
 value of the RSUs was determined on the date of grant, and
 compensation expense related to the RSUs is recognized once the
 related milestone is deemed probable. The Company recorded no
 expense during the nine months ended September&amp;#xA0;30, 2013
 related to the vesting of these RSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In February 2012, the
 Company granted 584,400 RSUs to several employees under the 2011
 Plan. As of September&amp;#xA0;30, 2013, a total of 90,684 RSUs were
 forfeited. These RSUs vest upon the achievement of certain
 regulatory and time-based milestones. The RSUs will become fully
 vested upon a change of control of the Company. Upon vesting of
 each RSU, the participant shall be entitled to a payment equal to
 the fair market value of one share of Amarin common stock. The
 payment shall be paid to the participant in cash, or at the sole
 discretion of the Compensation Committee in shares or a combination
 of cash or shares. During the nine months ended September&amp;#xA0;30,
 2013 and 2012, the Company issued 93,048 and 97,398 shares,
 respectively, as a result of the vesting of these RSUs. The fair
 value of the RSUs was determined on the date of grant, and
 compensation expense related to the RSUs is recognized once the
 related milestone is deemed probable. During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, the Company recorded expense of
 $0.3 million and $1.2 million, respectively, related to the vesting
 of these RSUs.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="3" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_1">0.001</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_4C96250E-471E-44A8-9AB6-6B6A087B624F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company states
 inventories at the lower of cost or market value. Cost is
 determined based on actual cost using the average cost method. An
 allowance is established when management determines that certain
 inventories may not be saleable. If inventory cost exceeds expected
 market value due to obsolescence, damage or quantities in excess of
 expected demand, the Company will record a reserve for the
 difference between cost and market value. The Company received FDA
 approval for Vascepa on July&amp;#xA0;26, 2012 and after that date
 began capitalizing inventory purchases of saleable product from
 approved suppliers. Until an API supplier is approved, all Vascepa
 API purchased from such supplier is included as a component of
 research and development expense. Upon sNDA approval of each
 additional supplier, the Company capitalizes subsequent Vascepa API
 purchases from such supplier as inventory. Purchases of Vascepa API
 received and expensed before such regulatory approvals is not
 subsequently capitalized, and all such purchases are quarantined
 and not used for commercial supply until such time as the sNDA for
 the supplier that produced the API is approved.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:DebtInstrumentCallDateEarliest contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_674A5308-E3DB-409A-850D-E5F2823646DE_1_0">2017-01-19</us-gaap:DebtInstrumentCallDateEarliest>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_8F826B9E-5ED6-4BC9-BADA-FAE92BB7A707_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
 and Cash Equivalents&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
 consist of cash, deposits held at call with banks and short term
 highly liquid instruments with remaining maturities at the date of
 purchase of 90&amp;#xA0;days or less. Restricted cash represents cash
 and cash equivalents pledged to guarantee repayment of certain
 expenses which may be incurred for business travel under corporate
 credit cards held by employees.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_21">-157255000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_0">386000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_526E763C-CFCB-49E6-A394-D0BDBF41DB8A_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Intangible
 Asset&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible asset consists
 of technology rights for Vascepa and have an estimated remaining
 useful life of 16.8 years. The carrying value as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 is as follows
 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
 rights&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated
 amortization&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(754&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(269&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,870&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,355&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_671E62FF-4BF2-4005-AD1D-0A43473D683A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
 Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three and nine
 months ended September&amp;#xA0;30, 2013 and 2012, the Company has
 reported its business as a single reporting segment. The
 Company&amp;#x2019;s chief decision maker, who is the Chief Executive
 Officer, regularly evaluates the Company on a consolidated
 basis.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_91A74ED8-CE8C-4EA2-B362-E9806B51F05C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying value as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 is as follows
 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
 rights&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated
 amortization&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(754&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(269&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,870&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,355&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_03F0DA79-D1A6-40B2-A459-6E4CE3ADA30C_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Significant Accounting
 Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of the
 Company&amp;#x2019;s consolidated financial statements in conformity
 with accounting principles generally accepted in the United States
 of America, or GAAP, requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. Accounting
 estimates are based on historical experience and other factors that
 are considered reasonable under the circumstances. Actual results
 could differ from those estimates. The preparation of the
 Company&amp;#x2019;s condensed consolidated financial statements in
 accordance with GAAP requires management to make estimates,
 judgments and assumptions that may affect the reported amounts of
 assets, liabilities, revenues and expenses, and related disclosure
 of contingent assets and liabilities. On an on-going basis, the
 Company evaluates its estimates and judgments and methodologies,
 including those related to revenue recognition and related
 allowances, clinical trial expenses, the valuation of inventory,
 impairment and amortization of intangibles, share-based
 compensation, income taxes including the valuation allowance for
 deferred tax assets, valuation of investments and derivative
 instruments. The Company bases its estimates on historical
 experience and on various other assumptions that are believed to be
 reasonable, the results of which form the basis for making
 judgments about the carrying values of assets and liabilities.
 Actual results may differ from these estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors, that in turn resell Vascepa to
 retail pharmacies for subsequent resale to patients and health care
 providers. Patients are required to have a prescription in order to
 purchase Vascepa. In accordance with GAAP, the Company&amp;#x2019;s
 revenue recognition policy requires that: (i)&amp;#xA0;there is
 persuasive evidence that an arrangement exists between the Company
 and the Distributor, (ii)&amp;#xA0;delivery has occurred,
 (iii)&amp;#xA0;collectability is reasonably assured and (iv)&amp;#xA0;the
 price is fixed or determinable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company commenced its
 commercial launch in the United States on January&amp;#xA0;28, 2013.
 Prior to 2013, the Company recognized no revenue from Vascepa
 sales. In accordance with GAAP, until the Company has the ability
 to reliably estimate returns of Vascepa from its Distributors,
 revenue will be recognized based on the resale of Vascepa for the
 purposes of filling patient prescriptions, and not based on sales
 from the Company to such Distributors. Consistent with industry
 practice, once the Company achieves sufficient history such that it
 can reliably estimate returns, the Company will recognize revenue
 based on sales to its Distributors. The Company currently defers
 Vascepa revenue recognition until the earlier of the product being
 resold for purposes of filling patient prescriptions; or the
 expiration of the right of return (twelve months after the
 expiration date of the product). The Company also defers the
 related cost of product sales and records such amounts as finished
 goods inventory held by others until revenue related to such
 product sales is recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contracts
 with its primary Distributors and delivery occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment or when the product is utilized.
 In order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&amp;#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&amp;#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues based on the wholesale acquisition cost that the
 Company charges its Distributors for Vascepa. The Company estimates
 its net product revenues by deducting from its gross product
 revenues (a)&amp;#xA0;trade allowances, such as invoice discounts for
 prompt payment and distributor fees, (b)&amp;#xA0;estimated government
 and private payor rebates, chargebacks and discounts, such as
 Medicaid reimbursements, (c)&amp;#xA0;reserves for expected product
 returns and (d)&amp;#xA0;estimated costs of incentives offered to
 certain indirect customers, including patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
 Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within
 30&amp;#xA0;days. Based on the Company&amp;#x2019;s judgment and experience,
 the Company expects its Distributors to earn these discounts and
 fees, and deducts the full amount of these discounts and fees from
 its gross product revenues and accounts receivable at the time such
 revenues are recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
 Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s contracts with these
 Third-party Payors, (ii)&amp;#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&amp;#xA0;information
 obtained from the Company&amp;#x2019;s Distributors and
 (iv)&amp;#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the 18-month period
 beginning six months prior to the labeled expiration date and
 ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. As of
 September&amp;#xA0;30, 2013, the Company had experienced a deminimus
 quantity of product returns. During the nine months ended
 September&amp;#xA0;30, 2013, the period in which the Company began
 selling Vascepa, the Company was not able to reasonably estimate
 product returns for all product sold to Distributors but the
 Company was able to reasonably estimate product returns for certain
 sales of Vascepa based on product used to fill patient
 prescriptions as determined by inventory estimated to be in the
 distribution channel and third party reports of prescriptions
 filled. In making this assessment, the Company used (i)&amp;#xA0;data
 provided to the Company by its Distributors (including weekly
 reporting of Distributors&amp;#x2019; sales and inventory held by
 Distributors that provided the Company with visibility into the
 distribution channel in order to determine what quantities were
 sold to retail pharmacies and other providers),
 (ii)&amp;#xA0;information provided to the Company from retail
 pharmacies, (iii)&amp;#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&amp;#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&amp;#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s
 Distributors.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
 Incentives:&amp;#xA0;&lt;/i&gt;Other incentives that the Company offers to
 indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&amp;#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&amp;#x2019;s portion of the
 financial responsibility for Vascepa&amp;#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company&amp;#x2019;s co-pay mitigation rebates offered
 to date will expire on December&amp;#xA0;31, 2013. The Company adjusts
 its accruals for co-pay mitigation rebates based on its estimates
 regarding the portion of issued rebates that it estimates will not
 be redeemed. In addition, as is customary prior to the launch of
 new drugs, the Company provided certain of its Distributors with
 financial incentives to begin stocking Vascepa prior to the
 Company&amp;#x2019;s commercial launch of Vascepa in order to ensure
 that Vascepa was readily available to fill patient prescriptions
 upon launch. Such incentives were only offered on purchases of
 initial launch quantities of Vascepa stocked by Distributors in
 January 2013. The amount of these financial incentives were
 recorded by the Company as a reduction to revenues on a pro-rata
 basis for each of the bottles subject to such financial incentives.
 The Company estimates that all of these initial launch quantities
 stocked by its primary Distributors in January 2013 were resold by
 such Distributors prior to September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,418&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,347&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,484&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,835&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;888&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;183&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,077&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product revenue
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred product
 revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,617&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;17,862&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 Company&amp;#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&amp;#xA0;30, 2013 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods sold
 expensed&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,813&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,454&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
 and Cash Equivalents&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
 consist of cash, deposits held at call with banks and short term
 highly liquid instruments with remaining maturities at the date of
 purchase of 90&amp;#xA0;days or less. Restricted cash represents cash
 and cash equivalents pledged to guarantee repayment of certain
 expenses which may be incurred for business travel under corporate
 credit cards held by employees.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company states
 inventories at the lower of cost or market value. Cost is
 determined based on actual cost using the average cost method. An
 allowance is established when management determines that certain
 inventories may not be saleable. If inventory cost exceeds expected
 market value due to obsolescence, damage or quantities in excess of
 expected demand, the Company will record a reserve for the
 difference between cost and market value. The Company received FDA
 approval for Vascepa on July&amp;#xA0;26, 2012 and after that date
 began capitalizing inventory purchases of saleable product from
 approved suppliers. Until an API supplier is approved, all Vascepa
 API purchased from such supplier is included as a component of
 research and development expense. Upon sNDA approval of each
 additional supplier, the Company capitalizes subsequent Vascepa API
 purchases from such supplier as inventory. Purchases of Vascepa API
 received and expensed before such regulatory approvals is not
 subsequently capitalized, and all such purchases are quarantined
 and not used for commercial supply until such time as the sNDA for
 the supplier that produced the API is approved.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
 of a milestone payment paid to the former shareholders of Laxdale
 Limited related to the 2004 acquisition of our rights to Vascepa,
 which is the result of Vascepa receiving marketing approval for the
 first indication and is amortized over its estimated useful life on
 a straight-line basis. The Company concluded that use of the
 straight-line method was appropriate as the majority of cash flows
 are expected to be generated ratably over the estimated useful life
 and no degradation of the cash flows over time is currently
 anticipated. See Note 7&amp;#x2014;Commitments and Contingencies for
 further information regarding other obligations related to the
 acquisition of Laxdale Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Deferred Revenue&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue represents
 product shipments to Distributors for which the Company has
 invoiced the Distributors but not recognized revenue because the
 product was not reported to the Company as having been resold for
 the purpose of filling prescriptions on or before
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
 Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges sales,
 general and administrative costs to operations as incurred.
 Selling, general and administrative costs include costs of
 salaries, programs and infrastructure necessary for the general
 conduct of the Company&amp;#x2019;s business, including the 2013
 commercial launch of Vascepa in the United States for the MARINE
 indication. Included as part of selling, general and administrative
 costs is warrant-related expense from non-cash changes in fair
 value of the derivative liability associated with warrants issued
 in October 2009 to former officers of Amarin which is recorded as
 compensation income (expense).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
 Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carry-forwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&amp;#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the statement of
 operations at each period end while such instruments are
 outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares. The warrants are valued using a
 Black-Scholes option pricing model due to the nature of the
 instrument. The long term debt redemption feature is valued using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. At the applicable settlement date, if the
 instruments are settled in shares, the carrying value of the
 warrants are derecognized and transferred to equity at their fair
 value at that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional paid-in
 capital.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
 per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &amp;#x201C;if-converted&amp;#x201D; method. In periods with reported net
 operating losses, all common stock options and warrants are deemed
 anti-dilutive such that basic net loss per share and diluted net
 loss per share are equal.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the statement
 of operations as interest expense at each period end while such
 instruments are outstanding. If the Company issues shares to
 discharge the liability, the debt obligation is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 exchangeable notes contain a conversion option which is classified
 as equity. The fair value of the liability component of the debt
 instrument was deducted from the initial proceeds to determine the
 proceeds to be allocated to the conversion option. The embedded
 conversion option is indexed to the Company&amp;#x2019;s stock and
 treated as equity on the balance sheet. The conversion option is
 evaluated on a quarterly basis to determine if it still meets the
 criteria to be equity classified. The excess principal amount of
 the debt over the carrying value of the liability is amortized to
 interest expense over the term of the debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 debt financing agreement contains a redemption
 feature triggered upon a change of control, which has been
 classified as an embedded derivative. The fair value of the
 derivative was recorded as a reduction to the fair value of the
 note payable. The fair value of this warrant derivative liability
 is remeasured at each reporting period, with changes in fair value
 recognized in the statement of operations. The discount recorded to
 the note payable is being amortized to interest expense over the
 term of the note payable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
 Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement
 date.&amp;#xA0;Fair value measurements may be classified based on the
 amount of subjectivity associated with the inputs to fair valuation
 of these assets and liabilities using the following three
 levels:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
 inputs that reflect the Company&amp;#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability.&amp;#xA0;The Company develops these inputs based on the
 best information available, including its own data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents information about the Company&amp;#x2019;s assets and
 liabilities as of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
 contracts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value because of their
 short-term nature.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Warrant Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2012,
 the fair value of the warrant derivative liability was determined
 to be $54.9 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.25%, (ii)&amp;#xA0;remaining term of 1.8 years, (iii)&amp;#xA0;no
 dividend yield, (iv)&amp;#xA0;volatility of 95% and (v)&amp;#xA0;the stock
 price on the date of measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At September&amp;#xA0;30, 2013,
 the fair value of the warrant derivative liability was determined
 to be $39.6 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.1%, (ii)&amp;#xA0;remaining term of 1.0 year, (iii)&amp;#xA0;no dividend
 yield, (iv)&amp;#xA0;volatility of 91%, and (v)&amp;#xA0;the stock price on
 the date of measurement.&amp;#xA0;The $3.6 million increase in the fair
 value of the warrant liability during the three months ended
 September&amp;#xA0;30, 2013 was recognized as: (i)&amp;#xA0;a $3.3 million
 loss on change in fair value of the remaining derivative liability
 and (ii)&amp;#xA0;$0.3 million in compensation expense for change in
 fair value of warrants issued to former employees. The $15.3
 million decrease in the fair value of the warrant liability during
 the nine months ended September&amp;#xA0;30, 2013 was recognized as:
 (i)&amp;#xA0;a $14.1 million gain on change in fair value of the
 remaining derivative liability and (ii)&amp;#xA0;$1.2 million in
 compensation income for change in fair value of warrants issued to
 former employees. Both amounts are included in the consolidated
 statement of operations for the nine months ended
 September&amp;#xA0;30, 2013.&amp;#xA0;The fair value of this warrant
 liability is determined using the Black-Scholes option valuation
 model and is therefore sensitive to changes in the market price and
 volatility of the Company&amp;#x2019;s common stock among other
 factors.&amp;#xA0;In the event of a hypothetical 10% increase in the
 market price of the Company&amp;#x2019;s common shares ($6.95 based on
 the $6.32 market price of the Company&amp;#x2019;s stock at
 September&amp;#xA0;30, 2013) on which the September&amp;#xA0;30, 2013
 valuation was based, the value of the derivative liability would
 have increased by $5.0 million.&amp;#xA0;Such increase would have been
 reflected as a loss on change in fair value of the warrant
 derivative liability in the Company&amp;#x2019;s statement of
 operations. Significant increases (decreases) in this input in
 isolation would result in a significantly higher (lower) fair value
 asset measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long
 Term Debt Redemption Feature&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman, L.P, or BioPharma, contains a redemption
 feature whereby, upon a change of control, the Company would be
 required to pay $140 million, less any previously repaid amount, if
 the change of control occurs on or before December&amp;#xA0;31, 2013,
 or required to repay $150 million, less any previously repaid
 amount, if the change of control event occurs after
 December&amp;#xA0;31, 2013. The Company determined this redemption
 feature to be an embedded derivative, which is carried at fair
 value and is classified as Level 3 in the fair value hierarchy due
 to the use of significant unobservable inputs.&amp;#xA0;The fair value
 of the embedded derivative was calculated using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two fair values of the debt was
 determined to be the fair value of the embedded derivative. At
 December&amp;#xA0;31, 2012, the fair value of the derivative was
 determined to be $14.6 million, and the debt was valued by
 comparing debt issues of similar companies with (i)&amp;#xA0;terms of
 between 4.8 and 8.0 years, (ii)&amp;#xA0;coupon rates of between 3.0%
 and 11.5% and (iii)&amp;#xA0;market yields of between 10.7% and 27.7%.
 At September&amp;#xA0;30, 2013, the fair value of the derivative was
 determined to be $7.2 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&amp;#xA0;remaining terms of
 between 3.5 and 4.4 years, (ii)&amp;#xA0;coupon rates of between 9.9%
 and 12.5% and (iii)&amp;#xA0;market yields of between 10.4% and 25.8%.
 The Company recognized a gain of $1.4 million and $7.4 million on
 the change in fair value of this derivative liability for the three
 and nine months ended September&amp;#xA0;30, 2013,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
 United States dollar as the functional currency. Monetary assets
 and liabilities denominated in a foreign currency are remeasured
 into United States dollars at period-end exchange rates.
 Non-monetary assets and liabilities carried in a foreign currency
 are remeasured into United States dollars using rates of exchange
 prevailing when such assets or liabilities were obtained or
 incurred, and expenses are generally remeasured using rates of
 exchange prevailing when such expenses are incurred. Gains and
 losses from the remeasurement are included in other (expense)
 income, net in the consolidated statements of operations. For
 transactions settled during the applicable period, gains and losses
 are included in other (expense) income, net in the consolidated
 statements of operations. The Company periodically uses foreign
 exchange forward contracts to hedge against changes in exchange
 rates for inventory purchases denominated in foreign currency. As
 of&amp;#xA0;September 30, 2013, the Company held one foreign exchange
 forward contract with a notional amount of $4.5 million. As
 of&amp;#xA0;September 30, 2013, the outstanding foreign exchange
 forward contract derivative liability had a net fair value of $0.4
 million. The Company included this $0.4 million as a component of
 change in fair value of derivative liabilities and in other current
 liabilities at September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of financial instruments is as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
 value of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,577&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,431&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,077&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,377&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;395&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;39,598&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,200&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;395&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;47,193&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
 Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three and nine
 months ended September&amp;#xA0;30, 2013 and 2012, the Company has
 reported its business as a single reporting segment. The
 Company&amp;#x2019;s chief decision maker, who is the Chief Executive
 Officer, regularly evaluates the Company on a consolidated
 basis.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
 Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are adopted by the Company as of the
 specified effective date. The Company believes that the impact of
 recently issued but not yet adopted accounting pronouncements will
 not have a material impact on consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&amp;#x2019;s operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_DE547759-A99B-4EFA-AD0A-1DC0B0919B0F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the statement of
 operations at each period end while such instruments are
 outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional paid-in capital are recognized on the
 issuance of those shares. The warrants are valued using a
 Black-Scholes option pricing model due to the nature of the
 instrument. The long term debt redemption feature is valued using a
 probability-weighted model incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. At the applicable settlement date, if the
 instruments are settled in shares, the carrying value of the
 warrants are derecognized and transferred to equity at their fair
 value at that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional paid-in
 capital.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_3B420B2D-7877-46F0-AAE3-FFF7003EC03E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
 United States dollar as the functional currency. Monetary assets
 and liabilities denominated in a foreign currency are remeasured
 into United States dollars at period-end exchange rates.
 Non-monetary assets and liabilities carried in a foreign currency
 are remeasured into United States dollars using rates of exchange
 prevailing when such assets or liabilities were obtained or
 incurred, and expenses are generally remeasured using rates of
 exchange prevailing when such expenses are incurred. Gains and
 losses from the remeasurement are included in other (expense)
 income, net in the consolidated statements of operations. For
 transactions settled during the applicable period, gains and losses
 are included in other (expense) income, net in the consolidated
 statements of operations. The Company periodically uses foreign
 exchange forward contracts to hedge against changes in exchange
 rates for inventory purchases denominated in foreign currency. As
 of&amp;#xA0;September 30, 2013, the Company held one foreign exchange
 forward contract with a notional amount of $4.5 million. As
 of&amp;#xA0;September 30, 2013, the outstanding foreign exchange
 forward contract derivative liability had a net fair value of $0.4
 million. The Company included this $0.4 million as a component of
 change in fair value of derivative liabilities and in other current
 liabilities at September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of financial instruments is as follows (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;123,125&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss on change in fair
 value of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,686&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation expense for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,037&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(103,885&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;90,963&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Warrants&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Redemption&amp;#xA0; &amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Feature&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Exchange&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;Contracts&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Totals&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;54,854&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;14,577&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;69,431&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,077&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,377&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;395&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,179&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfers to
 equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;39,598&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,200&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;395&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;47,193&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_5334E423-AE61-4BBD-B466-982E40B330AF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of the
 Company&amp;#x2019;s consolidated financial statements in conformity
 with accounting principles generally accepted in the United States
 of America, or GAAP, requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. Accounting
 estimates are based on historical experience and other factors that
 are considered reasonable under the circumstances. Actual results
 could differ from those estimates. The preparation of the
 Company&amp;#x2019;s condensed consolidated financial statements in
 accordance with GAAP requires management to make estimates,
 judgments and assumptions that may affect the reported amounts of
 assets, liabilities, revenues and expenses, and related disclosure
 of contingent assets and liabilities. On an on-going basis, the
 Company evaluates its estimates and judgments and methodologies,
 including those related to revenue recognition and related
 allowances, clinical trial expenses, the valuation of inventory,
 impairment and amortization of intangibles, share-based
 compensation, income taxes including the valuation allowance for
 deferred tax assets, valuation of investments and derivative
 instruments. The Company bases its estimates on historical
 experience and on various other assumptions that are believed to be
 reasonable, the results of which form the basis for making
 judgments about the carrying values of assets and liabilities.
 Actual results may differ from these estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_AFA8C7EB-FE9B-4729-80F4-E256994A8A23_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Nature of Business and
 Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Nature
 of Business&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin Corporation plc,
 &amp;#x201C;Amarin&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;, is a public
 limited company with its primary stock market listing in the United
 States on the NASDAQ Global Market. Amarin was originally
 incorporated in England as a private limited company on
 March&amp;#xA0;1, 1989 under the Companies Act 1985, and re-registered
 in England as a public limited company on March&amp;#xA0;19,
 1993.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin is a
 biopharmaceutical company with expertise in lipid science focused
 on the commercialization and development of therapeutics to improve
 cardiovascular health. On July&amp;#xA0;26, 2012, the Company received
 approval from the U.S. Food and Drug Administration, or FDA, to
 market and sell its lead product Vascepa&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 (icosapent ethyl) capsules (formerly known as AMR 101) as an
 adjunct to diet to reduce triglyceride levels in adult patients
 with severe (TG &lt;u&gt;&amp;gt;&lt;/u&gt;500mg/dL) hypertriglyceridemia, which
 the Company sometimes refers to as the MARINE indication.
 Triglycerides are fats in the blood. Vascepa became commercially
 available in the United States by prescription in January 2013,
 when the Company commenced sales and shipments to its network of
 U.S.-based wholesalers and specialty pharmacy providers. On
 January&amp;#xA0;28, 2013, the Company commenced its full commercial
 launch of Vascepa in the United States for use in the MARINE
 indication.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin is also developing
 Vascepa for the treatment of patients with high triglyceride levels
 (TG &lt;u&gt;&amp;gt;&lt;/u&gt;200 mg/dL and &amp;lt;500 mg/dL) who are also on statin
 therapy for elevated LDL-C levels. This indication is referred to
 as mixed dyslipidemia or the ANCHOR indication. In February 2013,
 the Company submitted a supplemental New Drug Application, or sNDA,
 to the FDA seeking approval of Vascepa for the ANCHOR indication.
 On October&amp;#xA0;16, 2013, the FDA convened an advisory committee to
 review the Company&amp;#x2019;s sNDA for the ANCHOR indication and the
 advisory committee voted 9 to 2 against recommending approval of
 the ANCHOR indication based on information presented at the
 meeting. The FDA will consider the recommendation of the advisory
 committee, but the final decision regarding the approval of the
 sNDA will be made by the FDA. The application is subject to a
 standard review and has been assigned a Prescription Drug User Fee
 Act, or PDUFA, date of December&amp;#xA0;20, 2013. The PDUFA date is
 the target date for the FDA to complete its review of the sNDA. The
 FDA could complete its review of the sNDA prior to this date and
 there can be no assurance that the FDA will complete its review of
 the sNDA by this date. If the FDA does not approve the ANCHOR
 indication, it would have a material impact on the Company&amp;#x2019;s
 future results of operations and financial condition (see Note
 9&amp;#x2014;Subsequent Events).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Basis
 of Presentation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The condensed consolidated
 financial statements included herein have been prepared by the
 Company, without audit, in accordance with accounting principles
 generally accepted in the United States of America (the
 &amp;#x201C;U.S.&amp;#x201D; or the &amp;#x201C;United States&amp;#x201D;) and pursuant
 to the rules and regulations of the Securities and Exchange
 Commission (the &amp;#x201C;SEC&amp;#x201D;). Certain information in the
 notes to the financial statements (the &amp;#x201C;Notes&amp;#x201D;) has
 been condensed or omitted where it substantially duplicates
 information provided in the Company&amp;#x2019;s latest audited
 consolidated financial statements, in accordance with the rules and
 regulations of the SEC. These condensed consolidated financial
 statements should be read in conjunction with the Company&amp;#x2019;s
 audited consolidated financial statements and notes included in its
 Annual Report on Form 10-K for the fiscal year ended
 December&amp;#xA0;31, 2012, filed with the SEC (the &amp;#x201C;2012 Form
 10-K&amp;#x201D;). The balance sheet amounts at December&amp;#xA0;31, 2012
 in this report were derived from the Company&amp;#x2019;s audited 2012
 consolidated financial statements included in the 2012 Form 10-K.
 The condensed consolidated financial statements reflect all
 adjustments that, in the opinion of management, are necessary to
 present fairly the Company&amp;#x2019;s financial position, results of
 operations and cash flows for the periods indicated. The
 preparation of financial statements in conformity with U.S.
 Generally Accepted Accounting Principles (&amp;#x201C;GAAP&amp;#x201D;)
 requires management to make estimates and assumptions that affect
 the reported amounts and classifications of assets and liabilities
 and disclosure of contingent assets and liabilities at the date of
 the financial statements and the reported amounts of revenues and
 expenses during the reporting period. The results of operations for
 the three and nine months ended September&amp;#xA0;30, 2013 and 2012,
 respectively, are not necessarily indicative of the results for the
 entire fiscal year or any future period. The Company has evaluated
 subsequent events from September&amp;#xA0;30, 2013 through the date of
 the issuance of these condensed consolidated financial statements
 and has disclosed subsequent events in Note 9.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The accompanying
 consolidated financial statements of the Company and subsidiaries
 have been prepared on a basis which assumes that the Company will
 continue as a going concern, which contemplates the realization of
 assets and the satisfaction of liabilities and commitments in the
 normal course of business. Prior to 2004, the Company was in the
 business of selling a previous biopharmaceutical compound, which
 has since been discontinued. The Company&amp;#x2019;s current focus is
 on the commercialization and development of Vascepa, which received
 approval from the FDA in 2012 and for which the Company commenced
 marketing and sales in 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At September&amp;#xA0;30, 2013,
 the Company had cash and cash equivalents of $225.9&amp;#xA0;million.
 See also Note 8&amp;#x2014;Equity for a description of a public offering
 completed in July 2013 resulting in net proceeds to the Company of
 approximately $121.2 million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 consolidated balance sheet also includes derivative liabilities
 (see Note 5&amp;#x2014;Warrants and Warrant Derivative Liability) as
 well as long term debt and exchangeable senior notes (see Note
 6&amp;#x2014;Debt). The warrant derivative liability reflects the fair
 value of outstanding warrants to purchase shares of the
 Company&amp;#x2019;s common stock. This liability can only be settled in
 shares of the Company&amp;#x2019;s stock. The long term debt is not
 callable except upon a change in control. The Exchangeable Senior
 Notes (the Notes) may be redeemed on or after January&amp;#xA0;19, 2017
 at the option of the holders. The Notes are exchangeable under
 certain circumstances into cash, American Depository Shares, or
 ADSs, or a combination of cash and ADSs, at the Company&amp;#x2019;s
 election. Accordingly, the warrant derivative liability, long term
 debt and Exchangeable Senior Notes do not present a short term
 claim on the liquid assets of the Company.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company believes its
 cash and cash equivalents will be sufficient to fund its projected
 operations for at least the next twelve months.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_E07B60E0-06A5-464D-A066-6D9D085BD329_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
 per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &amp;#x201C;if-converted&amp;#x201D; method. In periods with reported net
 operating losses, all common stock options and warrants are deemed
 anti-dilutive such that basic net loss per share and diluted net
 loss per share are equal.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_8836C1A4-2FDE-4E91-8279-AB57E7A8EF29_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
 Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement
 date.&amp;#xA0;Fair value measurements may be classified based on the
 amount of subjectivity associated with the inputs to fair valuation
 of these assets and liabilities using the following three
 levels:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
 inputs that reflect the Company&amp;#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability.&amp;#xA0;The Company develops these inputs based on the
 best information available, including its own data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents information about the Company&amp;#x2019;s assets and
 liabilities as of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012 that are measured at fair value on a recurring basis and
 indicates the fair value hierarchy of the valuation techniques the
 Company utilized to determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,
 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113.5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;39.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7.2&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency
 contracts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.4&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In millions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;64.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liability:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54.9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt redemption
 feature&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts receivable, accounts payable and
 accrued liabilities approximate fair value because of their
 short-term nature.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_14">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_EF0A4F54-A449-41AF-98E5-BB9E6F9A3180_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;/p&gt;
 &lt;table style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; LETTER-SPACING: normal; BORDER-COLLAPSE: collapse; FONT-FAMILY: &apos;Times New Roman&apos;; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;&lt;b&gt;Subsequent
 Events&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On October&amp;#xA0;16, 2013, the Company announced that an
 advisory committee to the FDA voted 9 to 2 against recommending
 approval of the use of Vascepa capsules for the ANCHOR indication
 based on information presented at the advisory committee meeting.
 The FDA is scheduled to make its decision on whether to approve the
 ANCHOR sNDA on the December&amp;#xA0;20, 2013 PDUFA goal date for the
 application, however, the FDA could complete its review of the sNDA
 prior to this date and there can be no assurance that the FDA will
 complete its review of the sNDA by this date.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On October&amp;#xA0;22, 2013, in an effort to reduce operating
 expenses following the recommendation of the advisory committee to
 the FDA, the Company implemented a worldwide reduction in force of
 approximately fifty percent of its staff positions worldwide. The
 majority of affected staff members are sales professionals who have
 supported the initial commercial launch of Vascepa. The Company
 estimates that it will incur approximately $3 million in charges
 related to the reduction in force, all of which includes cash
 expenditures for one-time termination benefits and associated
 costs. The Company expects to record the charges in the fourth
 quarter of 2013 and make the related payments by the end of the
 first quarter of 2014.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On October&amp;#xA0;29, 2013, the FDA notified the Company that it
 has rescinded the ANCHOR study Special Protocol Assessment, or SPA,
 agreement because in their view a substantial scientific issue
 essential to determining the effectiveness of Vascepa in the
 studied population from the ACCORD-Lipid and AIM-HIGH outcome
 trials, as well as the publicly presented results from the
 HPS2-THRIVE outcome trial, which the FDA stated in its
 October&amp;#xA0;29, 2013 notice to the Company, fail to support the
 hypothesis that a triglyceride-lowering drug significantly reduces
 the risk for cardiovascular events among statin-treated patients.
 Thus, the FDA stated that it no longer considers a change in serum
 triglyceride levels as sufficient to establish the effectiveness of
 a drug intended to reduce cardiovascular risk in subjects with
 serum triglyceride levels below 500 mg/dL.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On November 1, 2013, a purported investor of Amarin filed a
 putative class action lawsuit against Amarin and the
 Company&amp;#x2019;s Chief Executive Officer in the U.S. District Court
 for the District of New Jersey, Steven Sklar v. Amarin Corporation
 plc and Joseph S. Zakrzewski, No. 13-cv-6954 (D.N.J. Nov. 1, 2013).
 The lawsuit alleges that, during the period July 9, 2009 through
 October 15, 2013, the Company misled investors regarding the
 FDA&amp;#x2019;s willingness to approve Vascepa&amp;#x2019;s ANCHOR
 indication and the potential relevance of data from the ongoing
 REDUCE-IT trial to that approval, thereby artificially inflating
 the price of the Company&amp;#x2019;s securities. Based on these
 allegations, the suit asserts claims under the Securities Exchange
 Act of 1934 and seeks unspecified monetary damages and
 attorneys&amp;#x2019; fees and costs. The Company believes that it has
 valid defenses and will vigorously defend against the
 claims.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium &apos;Times New Roman&apos;; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;font size="2"&gt;&lt;font style="FONT-FAMILY: &apos;Times New Roman&apos;" size="2"&gt;On November 5, 2013, a purported investor of Amarin filed a
 putative class action lawsuit against Amarin and certain of the
 Company&amp;#x2019;s officers in the U.S. District Court for the
 Southern District of New York, Joseph A. Bove and Joseph J. Bove v.
 Amarin Corporation, PLC., Joseph S. Zakrzewski, John F. Thero, and
 Steven B. Ketchum, No. 13-CIV-7882 (S.D.N.Y. Nov. 5, 2013). The
 lawsuit alleges, similar to the&amp;#xA0;&lt;i&gt;Sklar&lt;/i&gt;&amp;#xA0;case, that, during the period
 August 8, 2012 until October 16, 2013, the Company misled investors
 regarding the FDA&amp;#x2019;s willingness to approve Vascepa&amp;#x2019;s
 ANCHOR indication and the potential relevance of data from the
 ongoing REDUCE-IT trial to that approval, thereby artificially
 inflating the price of the Company&amp;#x2019;s securities. Based on
 these allegations, the suit asserts claims under the Securities
 Exchange Act of 1934 and seeks unspecified monetary damages and
 attorneys&amp;#x2019; fees and costs. The Company believes that it has
 valid defenses and will vigorously defend against the
 claims.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_F994BDC1-789E-4113-929F-22E6422209B2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1_2">P1Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_F7744D13-3636-47A1-954E-AAC01451FB5B_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Royalty
 and Milestone Obligations&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company is party to
 certain milestone and royalty obligations under several product
 development agreements, as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company&amp;#x2019;s active pharmaceutical ingredient, or API,
 supply agreement with Nisshin Pharma, Inc. (&amp;#x201C;Nisshin&amp;#x201D;),
 provided for minimum supply purchase obligations on behalf of the
 Company to enable Amarin to maintain exclusivity with this
 supplier, and to prevent potential termination of the agreement
 based on Company estimated minimum purchase requirements. As of
 September&amp;#xA0;30, 2013, the API aggregate minimum purchase
 obligations under this supply agreement had been achieved and as a
 result, the Company has no future minimum purchase obligation from
 Nisshin.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In 2011, the Company entered into agreements with two
 additional suppliers, Chemport, Inc. (&amp;#x201C;Chemport&amp;#x201D;) and
 BASF (formerly Equateq Limited) for the supply of API materials for
 Vascepa. In 2012, the Company agreed to terms with a fourth API
 supplier, Slanmhor Pharmaceutical, Inc., or Slanmhor. These
 agreements include requirements for the suppliers to qualify their
 materials and facilities with applicable regulatory authorities
 including the FDA. The Company anticipates incurring certain costs
 associated with the qualification of product produced by these
 suppliers as described below. In each case, following qualification
 of the supplier for the manufacture of API for commercial sale,
 these agreements include annual purchase levels to enable Amarin to
 maintain exclusivity with each respective supplier, and to prevent
 potential termination of the agreements. The Company is not
 obligated to pay in cash any shortfall in the minimum purchase
 obligations pursuant to the Chemport and BASF agreements. The
 agreement with Slanmhor contains a provision requiring the Company
 to pay Slanmhor in cash for any shortfall in the minimum purchase
 obligations, which will become effective upon the approval for
 manufacture by the FDA of supply from Slanmhor. Chemport and BASF
 were approved by the FDA to manufacture API for commercial sale in
 April 2013. The Company has begun to purchase commercial supply
 from Chemport. BASF must complete production of validation batches
 before the Company will begin to purchase commercial supply. The
 2011 supply agreements include commitments for the Company to fund
 (i)&amp;#xA0;development fees up to a maximum of $0.5&amp;#xA0;million
 (ii)&amp;#xA0;material purchases of up to $5.0 million for initial raw
 materials, which amount will be credited against future API
 purchases and (iii)&amp;#xA0;a raw material purchase commitment of
 $1.1&amp;#xA0;million. Under these agreements, during the nine months
 ended September&amp;#xA0;30, 2013, the Company made payments of $4.8
 million and $0.1 million to Chemport and BASF, respectively. The
 agreement with Slanmhor provides for development fees of up to $2.3
 million and a commitment of up to $15.0 million, which will be
 credited against future API material purchases. The $15.0 million
 commitment fee is contingent upon the mutually agreed upon
 expansion of Slanmhor&amp;#x2019;s API manufacturing capacity. Under
 this agreement, during the nine months ended September&amp;#xA0;30,
 2013, the Company made payments of $6.1 million to Slanmhor related
 to stability and technical batches and advances on future API
 purchases.&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="2%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2022;&lt;/font&gt;&lt;/td&gt;
 &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Under the 2004 share repurchase agreement with Laxdale Limited,
 or Laxdale, upon approval of Vascepa by the FDA on July&amp;#xA0;26,
 2012, the Company was required to make a milestone payment to
 Laxdale of &amp;#xA3;7.5&amp;#xA0;million. The Company made this payment in
 2012 and capitalized this Laxdale milestone ($11.6 million on
 July&amp;#xA0;26, 2012) as an intangible asset. This long-term asset is
 being amortized over the estimated useful life of the intellectual
 property the Company acquired from Laxdale and the Company
 recognized amortization expense of $0.5 million during the nine
 months ended September&amp;#xA0;30, 2013. Also under the Laxdale
 agreement, upon receipt of marketing approval in Europe for the
 first indication for Vascepa (or first indication of any product
 containing Amarin Neuroscience intellectual property acquired from
 Laxdale in 2004), the Company must make an aggregate stock or cash
 payment to the former shareholders of Laxdale (at the sole option
 of each of the sellers) of &amp;#xA3;7.5&amp;#xA0;million (approximately
 $12.1 million at September&amp;#xA0;30, 2013). Also under the Laxdale
 agreement, upon receipt of a marketing approval in the U.S. or
 Europe for a further indication of Vascepa (or further indication
 of any other product using Amarin Neuroscience intellectual
 property), the Company must make an aggregate stock or cash payment
 (at the sole option of each of the sellers) of &amp;#xA3;5&amp;#xA0;million
 (approximately $8.1 million at September&amp;#xA0;30, 2013) for each of
 the two potential market approvals (i.e. &amp;#xA3;10&amp;#xA0;million
 maximum, or approximately $16.1 million at September&amp;#xA0;30,
 2013).&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company has no provision
 for any of the obligations above since the amounts are either not
 probable or estimable at September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900003">121206000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_24">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_15">1400000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_7">21059000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900007">627000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_40">1395000</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_9">-838000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_8">-26646000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_7">966000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_18">283000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5005_2">7347000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_39">5250000</us-gaap:InterestPaid>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_10">-155643000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_16">3721000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_0">16245000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_19">384000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_6">-149218000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_2_2">7400000</us-gaap:GainOnDerivativeInstrumentsPretax>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900008">966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_12">-150816000</us-gaap:NetIncomeLoss>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_32">7000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_17">5821000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900011">14170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_2">7813000</us-gaap:CostOfGoodsSold>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_11">-6389000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_10">13232000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_33">122912000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_30">966000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_3">179000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_34">-34357000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_20">-1714000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_8">8381000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_5">165463000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_4">101502000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_11">-4827000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_29">120000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5005_3">5270000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_27">121206000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_28">627000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_9">485000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:DirectOperatingCosts contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_93C82523-9507-4569-B77F-B34C2F307077_1_2">8454000</us-gaap:DirectOperatingCosts>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_25">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_3">56148000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_6">27000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_3_16">157105</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <amrn:ProductSales contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_FE09FBCA-69E5-4850-909A-245A033C95A9_1_2">17862000</amrn:ProductSales>
  <amrn:RecentAccountingPronouncementsPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_788FE4D0-39B4-43C8-A6C4-10004CBC9574_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
 Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are adopted by the Company as of the
 specified effective date. The Company believes that the impact of
 recently issued but not yet adopted accounting pronouncements will
 not have a material impact on consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&amp;#x2019;s operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:RecentAccountingPronouncementsPolicyTextBlock>
  <amrn:DeferredRevenuePolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_EF0B4EB2-19B3-47E6-BCC1-86657D3711AC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Deferred Revenue&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue represents
 product shipments to Distributors for which the Company has
 invoiced the Distributors but not recognized revenue because the
 product was not reported to the Company as having been resold for
 the purpose of filling prescriptions on or before
 September&amp;#xA0;30, 2013.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:DeferredRevenuePolicyTextBlock>
  <amrn:RevenuesTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_6DED42BF-3A73-4E43-9CFA-4C623A593F11_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes product revenue recognized and deferred during the nine
 months ended September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Product revenue
 recognized&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,245&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred product
 revenue&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,617&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;17,862&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:RevenuesTableTextBlock>
  <amrn:SummaryOfValuationAllowancesTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_83344DD5-0B62-4463-8311-C7D30E6EFB15_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the product revenue allowance and
 reserve categories described above for the nine months ended
 September&amp;#xA0;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 January&amp;#xA0;1, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,839&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,418&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;72&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,347&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period and deferred sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,484&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,835&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;888&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;934&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;72&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;183&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,077&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:SummaryOfValuationAllowancesTableTextBlock>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_3">120000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:ScheduleOfCostOfRevenueTableTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_D95DC88D-EC98-4F40-B5C5-3651C862660E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 Company&amp;#x2019;s recognition and deferral of product revenues, the
 Company expensed and capitalized the associated cost of goods, as
 follows, during the nine months ended September&amp;#xA0;30, 2013 (in
 thousands):&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="14%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cost of goods sold
 expensed&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,813&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods inventory
 held by others&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,454&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:ScheduleOfCostOfRevenueTableTextBlock>
  <amrn:ProceedsFromStockOptionExerciseAndOther contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_2">600000</amrn:ProceedsFromStockOptionExerciseAndOther>
  <amrn:SignificantAssumptionsInMarketPriceOfStock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_1_3">0.10</amrn:SignificantAssumptionsInMarketPriceOfStock>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900010">27000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:CashDiscountInvoiceTerms contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" id="id_2597911_1349199C-F8FD-4AA1-B735-F2AFAE180B22_1_1">P30D</amrn:CashDiscountInvoiceTerms>
  <amrn:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_5">100000</amrn:ProceedsFromExerciseOfStockOptionsAndWarrants>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9006_900004">120000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:ProceedsFromStockOptionsExercisedGross contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_1">600000</amrn:ProceedsFromStockOptionsExercisedGross>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_1_4">100000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:IncreaseDecreaseInLeaseRelatedLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1_12">3000</amrn:IncreaseDecreaseInLeaseRelatedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x711289" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_1002_3">9700000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x796972" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_2002_4">2200000</us-gaap:InterestExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x750970_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_1001_6">1900000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_1002_3">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_1002_2">32500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-6" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_1002_4">0</us-gaap:RestrictedStockExpense>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x784846" unitRef="iso4217_USD" decimals="-5" id="id_2597911_4FC3D6D7-5949-4643-9AB9-201691591606_1001_2">5000000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_1002_3">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_1002_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-6" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_1002_4">0</us-gaap:RestrictedStockExpense>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1001_2">93048</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1001_1">90684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-5" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1001_3">300000</us-gaap:RestrictedStockExpense>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600003">104805000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600007">335000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600008">966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600006">-71000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600011">14170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600010">24000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9003_600004">29000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400002">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400005">93048</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400007">386000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500003">16401000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500007">292000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500006">71000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="0" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400009">4032</amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_400004">120000</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500010">3000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9001_500004">91000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_9005_800012">-150816000</us-gaap:NetIncomeLoss>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x709050" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5001_2">2839000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x709050" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5001_3">1951000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x713749" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5003_2">72000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x824442" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5004_2">2018000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x824442" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5004_3">1835000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x825682" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5002_2">2418000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x825682" unitRef="iso4217_USD" decimals="-3" id="id_2597911_7C9E1F6D-0FEF-45B5-9A09-1E978FEC5596_5002_3">1484000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711196x826933_714378x714242" unitRef="pure" decimals="4" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_1001_0">113.4752</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711196x826933_714378x714242" unitRef="shares" decimals="INF" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_1001_1">17021280</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6004_2">21059000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x710071" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6003_2">-395000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x711232" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6002_2">7377000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_6001_2">14077000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1003_11">P3Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1003_15">0.104</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1003_13">0.099</amrn:FairValueInputsCouponRate>
  <amrn:MaturityPeriodUsedToClassifyInvestments contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112" id="id_2597911_062753C6-15FB-4582-AFDC-FFB1C2C4678E_1001_0">P90D</amrn:MaturityPeriodUsedToClassifyInvestments>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2003_12">P4Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2003_16">0.258</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2003_14">0.125</amrn:FairValueInputsCouponRate>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x785391" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_1001_7">15000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:DevelopmentFeesCommitted contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x785391" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_1001_6">2300000</amrn:DevelopmentFeesCommitted>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x819032" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_2001_2">5000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:DevelopmentFeesCommitted contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x819032" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_2001_1">500000</amrn:DevelopmentFeesCommitted>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1001_5">-1179000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_4FB89B59-F582-4D89-9326-47D8BA374E65_7001_3">-1179000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_4">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003" unitRef="iso4217_USD" decimals="-6" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1002_2">47000000000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x740402" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2001_4">14170000</us-gaap:ShareBasedCompensation>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_713399x715581" id="id_2597911_EF0A994A-606C-4B8D-8A67-D556ED63FBEE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Warrant Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2012,
 the fair value of the warrant derivative liability was determined
 to be $54.9 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.25%, (ii)&amp;#xA0;remaining term of 1.8 years, (iii)&amp;#xA0;no
 dividend yield, (iv)&amp;#xA0;volatility of 95% and (v)&amp;#xA0;the stock
 price on the date of measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At September&amp;#xA0;30, 2013,
 the fair value of the warrant derivative liability was determined
 to be $39.6 million using the Black-Scholes option valuation model
 applying the following assumptions: (i)&amp;#xA0;risk-free rate of
 0.1%, (ii)&amp;#xA0;remaining term of 1.0 year, (iii)&amp;#xA0;no dividend
 yield, (iv)&amp;#xA0;volatility of 91%, and (v)&amp;#xA0;the stock price on
 the date of measurement.&amp;#xA0;The $3.6 million increase in the fair
 value of the warrant liability during the three months ended
 September&amp;#xA0;30, 2013 was recognized as: (i)&amp;#xA0;a $3.3 million
 loss on change in fair value of the remaining derivative liability
 and (ii)&amp;#xA0;$0.3 million in compensation expense for change in
 fair value of warrants issued to former employees. The $15.3
 million decrease in the fair value of the warrant liability during
 the nine months ended September&amp;#xA0;30, 2013 was recognized as:
 (i)&amp;#xA0;a $14.1 million gain on change in fair value of the
 remaining derivative liability and (ii)&amp;#xA0;$1.2 million in
 compensation income for change in fair value of warrants issued to
 former employees. Both amounts are included in the consolidated
 statement of operations for the nine months ended
 September&amp;#xA0;30, 2013.&amp;#xA0;The fair value of this warrant
 liability is determined using the Black-Scholes option valuation
 model and is therefore sensitive to changes in the market price and
 volatility of the Company&amp;#x2019;s common stock among other
 factors.&amp;#xA0;In the event of a hypothetical 10% increase in the
 market price of the Company&amp;#x2019;s common shares ($6.95 based on
 the $6.32 market price of the Company&amp;#x2019;s stock at
 September&amp;#xA0;30, 2013) on which the September&amp;#xA0;30, 2013
 valuation was based, the value of the derivative liability would
 have increased by $5.0 million.&amp;#xA0;Such increase would have been
 reflected as a loss on change in fair value of the warrant
 derivative liability in the Company&amp;#x2019;s statement of
 operations. Significant increases (decreases) in this input in
 isolation would result in a significantly higher (lower) fair value
 asset measurement.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_1001_2">P24M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_0">P24M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_3">15000000</us-gaap:InterestExpenseDebt>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_5">9200000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2001_4">3900000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_981EFCF9-3AA2-400F-BBDC-3448AB47D971_1001_0">23800000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:EmbeddedDerivativeDescriptionOfHostContract contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_714777x781108_716763x740788" id="id_2597911_7F878E9E-D8EE-41BB-9795-4232131D4A48_1001_0">The warrants issued in connection with the October 2009 financing contained apricing variability feature which provided for an increase to the exercise priceif the exchange rate between the U.S. dollar and British pound adjusts such thatthe warrants could be exercised at a price less than the 0.5 par value of thecommon stock - that is, if the exchange rate exceeded U.S. $3.00 per 1.0sterling. Due to the potential variable nature of the exercise price, thewarrants are not considered to be indexed to the Company&apos;s common stock.Accordingly, the warrants do not qualify for the exception to classify thewarrants within equity and are classified as a derivative liability.</us-gaap:EmbeddedDerivativeDescriptionOfHostContract>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3003_9">7400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x716981_715990x713938" unitRef="iso4217_USD" decimals="-5" id="id_2597911_7740EE47-7093-403F-9241-796D7DDCD866_1001_3">400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1001_6">14100000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1001_7">-1200000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1001_5">-15300000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x840926" unitRef="iso4217_USD" decimals="-5" id="id_2597911_4BA651FB-DADC-4840-BF05-FE6CC569E5B1_1001_1">100000</us-gaap:ProceedsFromWarrantExercises>
  <amrn:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x840926" unitRef="shares" decimals="INF" id="id_2597911_4BA651FB-DADC-4840-BF05-FE6CC569E5B1_1001_0">120000</amrn:ClassOfWarrantOrRightExercisedInPeriod>
  <us-gaap:AdjustmentForAmortization contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x740537" unitRef="iso4217_USD" decimals="-5" id="id_2597911_ABB410A3-C9F0-413C-B59B-2A47E45AD9E5_1003_3">500000</us-gaap:AdjustmentForAmortization>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x770274" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_3001_5">100000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x775542" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_4001_4">4800000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x781952" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_5001_8">6100000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x819032" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_6001_3">1100000</us-gaap:LongTermPurchaseCommitmentAmount>
  <amrn:NumberOfAgreements contextRef="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x819032" unitRef="Contract" decimals="0" id="id_2597911_6673B4A3-47A3-409E-953E-498A96785D18_6001_0">2</amrn:NumberOfAgreements>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_21">-78539000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_0">3107913</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_14">-1.19</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900016">103885000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_24">477000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_7">-68686000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_23">1238000</us-gaap:PaymentsToAcquireLongtermInvestments>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900018">7834000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_40">697000</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_9">-411000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_8">-12838000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_7">10106000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_18">2273000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_39">2713000</us-gaap:InterestPaid>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_10">-162729000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_19">17355000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_6">-80794000</us-gaap:OperatingIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900017">22898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900019">10106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_12">-168617000</us-gaap:NetIncomeLoss>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_32">20000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_17">8989000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900024">13344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_10">9365000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_33">178762000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_30">10106000</us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_3">123000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_34">98508000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_20">33075000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_8">1094000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_5">80794000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_4">41059000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_31">144316000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_11">5888000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_29">16526000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_28">7834000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_9">108000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_25">-1715000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_3">39735000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_6">24000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_4_16">141947</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_5004_4">103885000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_3">10881276</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:ProceedsFromStockOptionExerciseAndOther contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_2">7800000</amrn:ProceedsFromStockOptionExerciseAndOther>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900023">24000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_5">16500000</amrn:ProceedsFromExerciseOfStockOptionsAndWarrants>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4006_900015">16526000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:ProceedsFromStockOptionsExercisedGross contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_1">7900000</amrn:ProceedsFromStockOptionsExercisedGross>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_1563AA52-FFDF-4F73-ACE1-49A5C6E85441_2_4">16600000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_42">103885000</amrn:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital>
  <amrn:IncreaseDecreaseInLeaseRelatedLiabilities contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2_12">-55000</amrn:IncreaseDecreaseInLeaseRelatedLiabilities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_708873x813756_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1002_2">97398</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_708873x813756_713115x715834_713879x768003" unitRef="iso4217_USD" decimals="-5" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_1002_3">1200000</us-gaap:RestrictedStockExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600016">103885000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600018">5395000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600017">22898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600019">10106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600021">-76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600024">13344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600023">23000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4003_600015">8119000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400020">97398</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400018">3107913</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500018">2439000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500021">76000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="0" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400022">2293</amrn:StockIssuedDuringPeriodSharesOfStockAndWarrantsForServices>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="shares" decimals="INF" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_400015">10881276</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500023">1000</amrn:StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4001_500015">8407000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_2597911_40D44C17-F2FB-454B-A6E9-3024B6120571_4005_800025">-168617000</us-gaap:NetIncomeLoss>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_6004_2">-68686000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_6001_2">-68686000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_1002_5">3037000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_7001_3">3037000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x740402" unitRef="iso4217_USD" decimals="-3" id="id_2597911_B179B5FD-1B5C-467A-988C-4DFC4F38C984_2002_4">13344000</us-gaap:ShareBasedCompensation>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1310-Q0010_STD_274_20120930_0_715632x740788" unitRef="iso4217_USD" decimals="-3" id="id_2597911_32399CE9-CE39-42ED-8ED2-5C35E101B82E_5001_4">103885000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_29_20120229_0_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_78085F95-519B-44A7-AFE4-BB7FE2357738_2003_0">584400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1001_9">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108" unitRef="iso4217_USD" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1001_2">3600000</us-gaap:DebtConversionOriginalDebtAmount1>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108" unitRef="pure" decimals="0" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_1001_10">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="shares" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_3">66400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_5">1.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="iso4217_USD" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_0">70000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="iso4217_USD" decimals="-5" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_1">62300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108" unitRef="pure" decimals="0" id="id_2597911_781D08CD-5066-4AE3-BB2B-2ABB5B06F8F5_2001_4">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0" unitRef="pure" decimals="2" id="id_2597911_DB29AC07-14C9-46D0-BC2B-72CC30A8D00F_1_0">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_2002_3">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" id="id_2597911_8D03C0E3-066F-40AB-A953-18E4FF9D66D4_2002_2">2012-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1001_3">144300000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242" id="id_2597911_C81A56F2-CAC6-4F34-855A-4A365BDD70FA_1001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_31_20130131_0_708321x810357_714378x716441" unitRef="iso4217_USD" decimals="-5" id="id_2597911_5E5412D7-D0D4-4411-A002-B4AC5761F192_1001_0">2600000</us-gaap:InterestPaid>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_31_20130131_0_713115x715834_713879x768003" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_2001_1">2015-08-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_31_20130131_0_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_E00ED253-0C2A-4F88-9757-F52882E4955F_2001_0">454875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1310-Q0010_STD_31_20130731_0_708321x810357_714378x716441" unitRef="iso4217_USD" decimals="-5" id="id_2597911_5E5412D7-D0D4-4411-A002-B4AC5761F192_1002_0">2600000</us-gaap:InterestPaid>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_4">0.95</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" unitRef="pure" decimals="INF" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_3">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" unitRef="pure" decimals="4" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_1">0.0025</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0" id="id_2597911_538A9757-F2B2-4DE7-B327-B013BC0D66E0_1_2">P1Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_707278x822778" unitRef="iso4217_USD" decimals="-5" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1002_0">100000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <amrn:AgreementExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_707278x822778" id="id_2597911_B6109AC0-19C2-48CD-B704-B07CD083DD0E_1002_7">2013-12-31</amrn:AgreementExpirationDate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1001_3">P4Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1001_7">0.107</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_1001_5">0.030</amrn:FairValueInputsCouponRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2001_4">P8Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2001_8">0.277</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueInputsCouponRate contextRef="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232" unitRef="pure" decimals="3" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_2001_6">0.115</amrn:FairValueInputsCouponRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="eol_PE46938---1310-Q0010_STD_61_20130930_0_713115x715834_713879x768003" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_2001_1">2013-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_61_20130930_0_713115x715834_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_483213D0-891A-4C90-9074-639C08A88D98_2001_0">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_14">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_7">16454000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_9">-427000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_8">-4570000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_10">-22853000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_6">-34310000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_12">-26426000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_5">34310000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_4">13397000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_11">3573000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_3">20913000</us-gaap:ResearchAndDevelopmentExpense>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_2_16">149200</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_14">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_7">-1402000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_9">-302000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_8">-8441000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_10">-50519000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:Revenues contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_0">8403000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_6">-40374000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainOnDerivativeInstrumentsPretax contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_3_2">1400000</us-gaap:GainOnDerivativeInstrumentsPretax>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_12">-48884000</us-gaap:NetIncomeLoss>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_2">3682000</us-gaap:CostOfGoodsSold>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_5">48777000</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_4">28274000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_11">-1635000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_3">16821000</us-gaap:ResearchAndDevelopmentExpense>
  <amrn:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_2597911_046EE8E6-3446-416A-A307-DB4E454BBA87_1_16">170187</amrn:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x711289" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_1003_3">2700000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x796972" unitRef="iso4217_USD" decimals="-5" id="id_2597911_C377772F-1A22-40AC-8919-88EDD42BD5C6_2003_4">600000</us-gaap:InterestExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_708873x750970_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_1002_6">700000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_713115x738662_713879x768003" unitRef="shares" decimals="INF" id="id_2597911_9E7202ED-46A3-44DC-ABA2-A57FCA54FA91_1001_0">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2002_3">5200000</us-gaap:InterestExpenseDebt>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2002_5">3200000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242" unitRef="iso4217_USD" decimals="-5" id="id_2597911_6BCEE560-6896-4353-930D-C136502BC815_2002_4">1300000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_715632x711232" unitRef="iso4217_USD" decimals="-5" id="id_2597911_2F3256B0-BC4B-4190-B5D7-D4438B899358_3005_9">1400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1002_6">-3300000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1002_7">300000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788" unitRef="iso4217_USD" decimals="-5" id="id_2597911_8403EB68-1175-4149-A7A7-454D2D4856F3_1002_5">3600000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_713115x738662_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:DeferredStockUnitsDSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_708873x750970_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:DebtOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x796972">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0_707278x822778_708873x711289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_61_20130930_0_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x716112_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0_711502x711169_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0_707278x822778">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20130731_0_708321x810357_714378x716441">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20130131_0_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20130131_0_708321x810357_714378x716441">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20120131_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20120131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20091031_0_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_31_20091031_0_711171x716792_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_29_20120229_0_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x740402">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_713115x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_711461x739938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0_708873x813756_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x819032">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:AmrOneHundredOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x781952">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x775542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x770274">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_735055x740537">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x840926">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedJulyTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x716981_715990x713938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713399x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x740402">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x738662_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:DeferredStockUnitsDSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_713115x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x819032">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:AmrOneHundredOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_735055x785391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:SupplierDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711502x711169_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938_715632x710071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711461x739938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DerivativeInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_711196x826933_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x825682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x824442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x713749">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709711x709050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x813756_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x808971_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x784846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x759819_713115x715834_713879x768003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:Group2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_708873x750970_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:DebtOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x796972">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0_707278x822778_708873x711289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_22_20131022_0_710720x714667">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-22</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_12_20130712_0_711196x826933">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-12</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_12_20130712_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-12</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_716763x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_710256x715225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x829211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x824056">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x796385">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x770088">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778_755443x735492">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0_707278x822778">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_716763x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x716981">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x711232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_715632x710071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x821234">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x815051">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x797754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_713399x725855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">amrn:WarrantFourMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_711672x709584_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_711502x716112_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_710256x715225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x825682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x824442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x713749">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709711x709050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x829979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FirstIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x834798_735055x740537_764190x779644">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FirstIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x830088_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ProceedsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x784846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x829979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_735055x740537_764190x779644">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_708873x783044_711502x716112_735055x740537">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0_707278x822778_755443x829211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_715632x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0_709650x708572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_711672x709584_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_711171x716792_714777x781108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20091016_0_708566x815040_711171x716792_714777x781108_716763x740788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20130712_0_711196x826933">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-12</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120726_0_735055x740537">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="amrn:LiabilitiesForCommitmentsAxis">amrn:LaxdaleLimitedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-07-26</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x826933">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20131101_0_711196x820302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1310-Q0010_STD_0_20120131_0_714378x714242">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>amrn:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="Contract">
    <measure>amrn:Contract</measure>
  </unit>
</xbrl>